<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nature</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
    <journal-title-group>
      <journal-title>Nature</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0028-0836</issn>
    <issn pub-type="epub">1476-4687</issn>
    <publisher>
      <publisher-name>Nature Publishing Group UK</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8458098</article-id>
    <article-id pub-id-type="pmid">34375979</article-id>
    <article-id pub-id-type="publisher-id">3855</article-id>
    <article-id pub-id-type="doi">10.1038/s41586-021-03855-y</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Rare variant contribution to human disease in 281,104 UK Biobank exomes</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Wang</surname>
          <given-names>Quanli</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8965-0813</contrib-id>
        <name>
          <surname>Dhindsa</surname>
          <given-names>Ryan S.</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Carss</surname>
          <given-names>Keren</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5327-0328</contrib-id>
        <name>
          <surname>Harper</surname>
          <given-names>Andrew R.</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Nag</surname>
          <given-names>Abhishek</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Tachmazidou</surname>
          <given-names>Ioanna</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Vitsios</surname>
          <given-names>Dimitrios</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0405-4335</contrib-id>
        <name>
          <surname>Deevi</surname>
          <given-names>Sri V. V.</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Mackay</surname>
          <given-names>Alex</given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Muthas</surname>
          <given-names>Daniel</given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Hühn</surname>
          <given-names>Michael</given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Monkley</surname>
          <given-names>Susan</given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5101-8871</contrib-id>
        <name>
          <surname>Olsson</surname>
          <given-names>Henric</given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author" id="IAu1">
        <collab>AstraZeneca Genomics Initiative<contrib-group><contrib contrib-type="author"><name><surname>Angermann</surname><given-names>Bastian R.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Artzi</surname><given-names>Ronen</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Barrett</surname><given-names>Carl</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Belvisi</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Bohlooly-Y</surname><given-names>Mohammad</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Burren</surname><given-names>Oliver</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Buvall</surname><given-names>Lisa</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Challis</surname><given-names>Benjamin</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Cameron-Christie</surname><given-names>Sophia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cohen</surname><given-names>Suzanne</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Davis</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Danielson</surname><given-names>Regina F.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Dougherty</surname><given-names>Brian</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Georgi</surname><given-names>Benjamin</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ghazoui</surname><given-names>Zara</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hansen</surname><given-names>Pernille B. L.</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Fengyuan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jeznach</surname><given-names>Magda</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Xiao</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Chanchal</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Lai</surname><given-names>Zhongwu</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Lassi</surname><given-names>Glenda</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Lewis</surname><given-names>Samuel H.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Linghu</surname><given-names>Bolan</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Lythgow</surname><given-names>Kieren</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Maccallum</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Martins</surname><given-names>Carla</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Matakidou</surname><given-names>Athena</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Michaëlsson</surname><given-names>Erik</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Moosmang</surname><given-names>Sven</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>O’Dell</surname><given-names>Sean</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ohne</surname><given-names>Yoichiro</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name><surname>Okae</surname><given-names>Joel</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>O’Neill</surname><given-names>Amanda</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Paul</surname><given-names>Dirk S.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Reznichenko</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Snowden</surname><given-names>Michael A</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Walentinsson</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Zeron</surname><given-names>Jorge</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Pangalos</surname><given-names>Menelas N.</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib></contrib-group></collab>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wasilewski</surname>
          <given-names>Sebastian</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Smith</surname>
          <given-names>Katherine R.</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>March</surname>
          <given-names>Ruth</given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3455-1789</contrib-id>
        <name>
          <surname>Platt</surname>
          <given-names>Adam</given-names>
        </name>
        <xref ref-type="aff" rid="Aff5">5</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5095-5716</contrib-id>
        <name>
          <surname>Haefliger</surname>
          <given-names>Carolina</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1527-961X</contrib-id>
        <name>
          <surname>Petrovski</surname>
          <given-names>Slavé</given-names>
        </name>
        <address>
          <email>slav.petrovski@astrazeneca.com</email>
        </address>
        <xref ref-type="aff" rid="Aff2">2</xref>
        <xref ref-type="aff" rid="Aff6">6</xref>
        <xref ref-type="aff" rid="Aff7">7</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.418152.b</institution-id><institution>Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&amp;D, </institution><institution>AstraZeneca, </institution></institution-wrap>Waltham, MA USA </aff>
      <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.417815.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 5929 4381</institution-id><institution>Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&amp;D, </institution><institution>AstraZeneca, </institution></institution-wrap>Cambridge, UK </aff>
      <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.418151.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 1519 6403</institution-id><institution>Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&amp;D, </institution><institution>AstraZeneca, </institution></institution-wrap>Gothenburg, Sweden </aff>
      <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.417815.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 5929 4381</institution-id><institution>Precision Medicine &amp; Biosamples, Oncology R&amp;D, </institution><institution>AstraZeneca, </institution></institution-wrap>Cambridge, UK </aff>
      <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.417815.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 5929 4381</institution-id><institution>Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&amp;D, </institution><institution>AstraZeneca, </institution></institution-wrap>Cambridge, UK </aff>
      <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.410678.c</institution-id><institution>Department of Medicine, </institution><institution>University of Melbourne, Austin Health, </institution></institution-wrap>Melbourne, Victoria Australia </aff>
      <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.410678.c</institution-id><institution>Epilepsy Research Centre, </institution><institution>University of Melbourne, Austin Health, </institution></institution-wrap>Melbourne, Victoria Australia </aff>
      <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.418152.b</institution-id><institution>Translational Medicine, Research and Early Development, Oncology R&amp;D, </institution><institution>AstraZeneca, </institution></institution-wrap>Waltham, MA USA </aff>
      <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.417815.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 5929 4381</institution-id><institution>Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&amp;D, </institution><institution>AstraZeneca, </institution></institution-wrap>Cambridge, UK </aff>
      <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.418151.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 1519 6403</institution-id><institution>Translational Genomics, Discovery Biology, Discovery Sciences, BioPharmaceuticals R&amp;D, </institution><institution>AstraZeneca, </institution></institution-wrap>Gothenburg, Sweden </aff>
      <aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.418151.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 1519 6403</institution-id><institution>Biosciences CKD, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&amp;D, </institution><institution>AstraZeneca, </institution></institution-wrap>Gothenburg, Sweden </aff>
      <aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="GRID">grid.418151.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 1519 6403</institution-id><institution>Translational Science &amp; Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&amp;D, </institution><institution>AstraZeneca, </institution></institution-wrap>Gothenburg, Sweden </aff>
      <aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.417815.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 5929 4381</institution-id><institution>Bioscience Asthma, Research and Early Development, Respiratory &amp; Immunology, Biopharmaceuticals R&amp;D, </institution><institution>AstraZeneca, </institution></institution-wrap>Cambridge, UK </aff>
      <aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="GRID">grid.418151.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 1519 6403</institution-id><institution>Discovery Sciences, BioPharmaceuticals R&amp;D, </institution><institution>AstraZeneca, </institution></institution-wrap>Gothenburg, Sweden </aff>
      <aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="GRID">grid.418151.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 1519 6403</institution-id><institution>Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&amp;D, </institution><institution>AstraZeneca, </institution></institution-wrap>Gothenburg, Sweden </aff>
      <aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="GRID">grid.417815.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 5929 4381</institution-id><institution>Oncology Discovery, Early Oncology, Oncology R&amp;D, </institution><institution>AstraZeneca, </institution></institution-wrap>Cambridge, UK </aff>
      <aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="GRID">grid.418151.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 1519 6403</institution-id><institution>Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&amp;D, </institution><institution>AstraZeneca, </institution></institution-wrap>Gothenburg, Sweden </aff>
      <aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="GRID">grid.418152.b</institution-id><institution>Bioscience Asthma, Research and Early Development, Respiratory &amp; Immunology, Biopharmaceuticals R&amp;D, </institution><institution>AstraZeneca, </institution></institution-wrap>Gaithersburg, MD USA </aff>
      <aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="GRID">grid.417815.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 5929 4381</institution-id><institution>Biopharmaceuticals R&amp;D, </institution><institution>AstraZeneca, </institution></institution-wrap>Cambridge, UK </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>10</day>
      <month>8</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>10</day>
      <month>8</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="ppub">
      <year>2021</year>
    </pub-date>
    <volume>597</volume>
    <issue>7877</issue>
    <fpage>527</fpage>
    <lpage>532</lpage>
    <history>
      <date date-type="received">
        <day>3</day>
        <month>11</month>
        <year>2020</year>
      </date>
      <date date-type="accepted">
        <day>28</day>
        <month>7</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s), under exclusive licence to Springer Nature Limited 2021</copyright-statement>
      <license>
        <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <p id="Par1">Genome-wide association studies have uncovered thousands of common variants associated with human disease, but the contribution of rare variants to common disease remains relatively unexplored. The UK Biobank contains detailed phenotypic data linked to medical records for approximately 500,000 participants, offering an unprecedented opportunity to evaluate the effect of rare variation on a broad collection of traits<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. Here we study the relationships between rare protein-coding variants and 17,361 binary and 1,419 quantitative phenotypes using exome sequencing data from 269,171 UK Biobank participants of European ancestry. Gene-based collapsing analyses revealed 1,703 statistically significant gene–phenotype associations for binary traits, with a median odds ratio of 12.4. Furthermore, 83% of these associations were undetectable via single-variant association tests, emphasizing the power of gene-based collapsing analysis in the setting of high allelic heterogeneity. Gene–phenotype associations were also significantly enriched for loss-of-function-mediated traits and approved drug targets. Finally, we performed ancestry-specific and pan-ancestry collapsing analyses using exome sequencing data from 11,933 UK Biobank participants of African, East Asian or South Asian ancestry. Our results highlight a significant contribution of rare variants to common disease. Summary statistics are publicly available through an interactive portal (<ext-link ext-link-type="uri" xlink:href="http://azphewas.com/">http://azphewas.com/</ext-link>).</p>
    </abstract>
    <abstract id="Abs2" abstract-type="web-summary">
      <p id="Par2">The authors analyse rare protein-coding genetic variants for association with 18,780 traits in the UK Biobank cohort.</p>
    </abstract>
    <kwd-group kwd-group-type="npg-subject">
      <title>Subject terms</title>
      <kwd>Genome-wide association studies</kwd>
      <kwd>Medical genetics</kwd>
      <kwd>Rare variants</kwd>
      <kwd>Genetics research</kwd>
    </kwd-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© The Author(s), under exclusive licence to Springer Nature Limited 2021</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Main</title>
    <p id="Par3">The identification of genetic variants that contribute to human disease has facilitated the development of highly efficacious and safe therapeutic agents<sup><xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR5">5</xref></sup>. Drug candidates targeting genes with evidence of human disease causality are in fact substantially more likely to be approved<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup>. Exome sequencing has revolutionized our understanding of rare diseases, uncovering causal rare variants for hundreds of these disorders. However, most efforts for complex human diseases and traits have relied on genome-wide association studies (GWAS), which focus on common variants. Compared with rare variants, common variants tend to confer smaller effect sizes and can be difficult to map to causal genes<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>.</p>
    <p id="Par4">The UK Biobank (UKB) offers an unprecedented opportunity to assess the contribution of both common and rare genetic variation to thousands of human traits and diseases<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR13">13</xref></sup>. Testing for the association between rare variants and phenotypes is typically performed at the variant or gene level. Gene-level association tests include collapsing analyses and burden tests, among others<sup><xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR17">17</xref></sup>. Collapsing analyses are particularly well suited to detect genetic risk for phenotypes driven by an allelic series<sup><xref ref-type="bibr" rid="CR16">16</xref>–<xref ref-type="bibr" rid="CR23">23</xref></sup> and can provide a clear link between the causal gene and phenotype. Applications of these methods to the first 50,000 UKB exome sequences have indicated an important role of rare variation in complex disease but have also highlighted a need for larger sample sizes<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>.</p>
    <p id="Par5">In this study, we performed a phenome-wide association study (PheWAS) using exome sequence data from 269,171 UKB participants of European ancestry to evaluate the association between protein-coding variants and 17,361 binary and 1,419 quantitative phenotypes. We first report the diversity of phenotypes and sequence variation present in this cohort. We then performed variant-level and gene-level association tests to identify risk factors across the allele frequency spectrum. Finally, we performed additional collapsing analyses in 11,933 individuals of African, East Asian or South Asian genetic ancestry. Using these results, we implemented a pan-ancestry analysis of 281,104 UKB participants. Altogether, this study comprehensively examines the contribution of rare protein-coding variation to the genetic architecture of complex human diseases and quantitative traits.</p>
  </sec>
  <sec id="Sec2">
    <title>Cohort characteristics</title>
    <p id="Par6">We processed 998 TB of raw exome sequence data from 302,355 UKB participants through a cloud-based bioinformatics pipeline (<xref rid="Sec8" ref-type="sec">Methods</xref>). Through stringent quality control, we removed samples with low sequencing quality and from closely related individuals (Methods). To harmonize variable categorization modes, scaling, and follow-up responses inherent to the phenotype data, we developed PEACOK, a modification of the PHESANT package<sup><xref ref-type="bibr" rid="CR24">24</xref></sup> (Methods).</p>
    <p id="Par7">We considered 17,361 binary traits and 1,419 quantitative traits, which we categorized into 22 ICD-10-based chapters (Extended Data Fig. <xref rid="Fig4" ref-type="fig">1a, b</xref>, Supplementary Table <xref rid="MOESM3" ref-type="media">1</xref>). We also computed the union of cases across similar phenotypes, resulting in 4,911 union phenotypes (Methods; Supplementary Table <xref rid="MOESM3" ref-type="media">1</xref>). The median number of European cases per binary union phenotype was 191 and the median number of individuals tested for quantitative traits was 13,782 (Extended Data Fig. <xref rid="Fig4" ref-type="fig">1c, d</xref>). The median number of binary union traits was 25 (Extended Data Fig. <xref rid="Fig4" ref-type="fig">1e</xref>).</p>
    <p id="Par8">Approximately 95% of the sequenced UKB participants are of European ancestry (Extended Data Fig. <xref rid="Fig4" ref-type="fig">1f</xref>). This affects health-care equity, as the resolution to evaluate variants across the allele frequency spectrum is proportional to the number of sequenced individuals in a population. For example, individuals from non-European ancestries showed a substantially higher number of rare (minor allele frequency (MAF) &lt; 0.005%), non-synonymous variants in Online Mendelian Inheritance in Man (OMIM) disease-associated genes (Extended Data Fig. <xref rid="Fig4" ref-type="fig">1g</xref>). This demonstrates a reduced resolution to accurately estimate lower variant frequencies in non-European populations, as previously observed<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>.</p>
  </sec>
  <sec id="Sec3">
    <title>Identifying protein-truncating variants</title>
    <p id="Par9">Protein-truncating variants (PTVs), which often inactivate proteins, provide direct insight into human biology and disease mechanisms<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>. Identifying PTVs that are protective against disease can also offer direct human validation of potential therapeutic targets<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>. Among 287,917 participants of any ancestry, we observed that 96% of 18,762 studied genes had at least one heterozygous PTV carrier, 46% had at least one compound heterozygous or homozygous/hemizygous PTV carrier, and 20% had at least one homozygous/hemizygous PTV carrier (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). Only 884 genes (4.7%) had PTVs with a MAF &gt; 0.5% (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>), illustrating the power of exome sequencing to detect this important form of variation. Although some have been implicated in human diseases, most common PTVs occur in genes that are less relevant to disease, such as olfactory receptor genes<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Focusing on rarer PTVs (MAF &lt; 1%), we observed that 95% of genes had at least one heterozygous PTV carrier, 42% had at least one compound heterozygous or homozygous/hemizygous PTV carrier, and only 15% had at least one homozygous/hemizygous PTV carrier (Extended Data Fig. <xref rid="Fig5" ref-type="fig">2a</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><title>Summary of variant-level exome-wide association study results.</title><p><bold>a</bold>, The number of genes (<italic>y</italic> axis) with at least the number of PTV carriers (<italic>x</italic> axis) in 287,917 UKB participants of any ancestry. The dashed line corresponds to the minimum number of carriers typically required to detect individual PTVs with a MAF &gt; 0.5%, that is, 2,873 carriers. Colours represent heterozygous (het.), putative compound heterozygous (comp. het.) and homozygous/hemizygous carriers (recessive). <bold>b</bold>, The MAF distribution of 632 genome-wide significant ExWAS variants associated with binary traits. The inset plot represents the same data limited to variants with MAF &lt; 0.5%. <bold>c</bold>, The distribution of effect sizes for 509 common versus 123 rare (MAF &lt; 0.5%) significant ExWAS variants. The plots in <bold>b</bold> and <bold>c</bold> include variants with the largest effect sizes achieved per gene. <bold>d</bold>, Percentage of ExWAS study-wide significant PTVs (<italic>n</italic> = 24) and missense variants (<italic>n</italic> = 326) that reflect known or novel gene–phenotype relationships. Variants capturing known gene–phenotype relationships were partitioned into those validated in (1) at least one but not all, or (2) all four publicly available databases: FinnGen release r5, OMIM, the GWAS Catalog (including GWAS Catalog variants within a 50-kb flanking sequence either side of the index variant), and the ClinVar pathogenic/likely pathogenic variant collection.</p></caption><graphic xlink:href="41586_2021_3855_Fig1_HTML" id="d33e786"/></fig></p>
  </sec>
  <sec id="Sec4">
    <title>Variant-level associations</title>
    <p id="Par10">Exome sequencing enables association tests between phenotypes and protein-coding variants across the allele frequency spectrum. We performed a variant-level exome-wide association study (ExWAS) to test for associations between all 18,780 phenotypes and 2,108,983 variants observed in at least six participants of European ancestry (that is, MAF &gt; 0.001%). We used three genetic models (Methods), equating to 118.8 billion tests. We used a two-sided Fisher’s exact test for binary traits and linear regression for quantitative traits. Using a <italic>P</italic> value threshold of <italic>P</italic> ≤ 2 × 10<sup>−9</sup> (Methods) and excluding the MHC region (chromosome 6: 25–35 Mb), we identified 5,193 significant genotype–phenotype associations for binary traits and 41,754 associations for quantitative traits (Supplementary Table <xref rid="MOESM3" ref-type="media">2</xref>, <xref rid="MOESM1" ref-type="media">3</xref>).</p>
    <p id="Par11">Many of the significant ExWAS signals arose from rare variants (MAF &lt; 0.5%) (Fig. <xref rid="Fig1" ref-type="fig">1b</xref>). The rarest significant variant was a frameshift variant in haemoglobin subunit-β (<italic>HBB</italic>) associated with thalassaemia (cohort MAF of 0.0013%) (Supplementary Table <xref rid="MOESM1" ref-type="media">3</xref>). In the dominant model, rare variants accounted for 26% of statistically significant associations. Furthermore, 21% (227 of 1,088) of binary trait associations and 12% (1,330 of 10,770) of quantitative trait associations identified using the recessive model were not detected using the dominant model. Associations with more common variants have previously been published<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>.</p>
    <p id="Par12">The effect sizes of significant rare variant associations were substantially higher than those of common variants (Wilcoxon <italic>P</italic> = 1.1 × 10<sup>−57</sup>) (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>). While some significant variants are probably in linkage with nearby causal variants, associated PTVs and missense variants often represent the causal variant themselves<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Notably, associations for 13% (3 of 24) and 29% (96 of 326) of the significant PTVs and missense variants, respectively, have not been reported in FinnGen release 5, OMIM, ClinVar or the GWAS catalogue<sup><xref ref-type="bibr" rid="CR30">30</xref>–<xref ref-type="bibr" rid="CR32">32</xref></sup> (Fig. <xref rid="Fig1" ref-type="fig">1d</xref>, Supplementary Table <xref rid="MOESM3" ref-type="media">4</xref>, <xref rid="MOESM3" ref-type="media">5</xref>).</p>
    <p id="Par13">We explored how often significant variant-level associations between different variants in the same gene have opposing directions of effect on a phenotype. Among quantitative trait associations with at least five significant non-synonymous variants (MAF &lt; 0.1%) in a particular gene, at least 80% of variants had the same direction of effect (Extended Data Fig. <xref rid="Fig5" ref-type="fig">2b</xref>). This is in contrast to disease-associated non-coding variants, which can variably affect the direction of gene expression<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>.</p>
    <p id="Par14">We compared the results of our Fisher’s exact tests to regression-based frameworks. While an exact test is robust for rarer variants, regression methods can incorporate covariates to help to mitigate confounders and are recommended when careful control for confounding cannot be ensured. We performed single-variant association tests across all autosomal variants for 324 Chapter IX binary phenotypes (diseases of the circulatory system; Supplementary Table <xref rid="MOESM3" ref-type="media">29</xref>) using SAIGE SPA<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> and REGENIE 2.0.2 (ref. <sup><xref ref-type="bibr" rid="CR34">34</xref></sup>), including sex, age, sequencing batch and ten principal components as covariates (<xref rid="MOESM1" ref-type="media">Supplementary Methods</xref>). Fisher’s exact Phred scores (−10 × log<sub>10</sub>(<italic>P</italic> values)) were strongly correlated with those from SAIGE SPA (Pearson’s <italic>r</italic> = 0.95) and REGENIE 2.0.2 (Pearson’s <italic>r</italic> = 0.94). Fisher’s exact <italic>P</italic> value statistics were also more conservative for lower frequency variants (MAF ≤ 1%) (Supplementary Table <xref rid="MOESM1" ref-type="media">6</xref>). Correlation was higher for signals with a <italic>P</italic> &lt; 1 × 10<sup>−8</sup> in either Fisher’s exact test or SAIGE SPA (Pearson’s <italic>r</italic> = 0.99) and Fisher’s exact test or REGENIE 2.0.2 (Pearson’s <italic>r</italic> = 0.99) (Supplementary Figs. <xref rid="MOESM1" ref-type="media">1</xref>, <xref rid="MOESM1" ref-type="media">2</xref>, Supplementary Table <xref rid="MOESM1" ref-type="media">6</xref>). The median lambda inflation factor <italic>λ</italic><sub>GC</sub> for the Fisher’s exact test was 1.0006 (range: 0.9675–1.0698) compared with a median <italic>λ</italic><sub>GC</sub> of 0.9953 (range: 0.9372–1.0940) for SAIGE SPA and a median <italic>λ</italic><sub>GC</sub> of 1.0001 (range: 0.9439–1.0602) for REGENIE 2.0.2 (Supplementary Table <xref rid="MOESM3" ref-type="media">7</xref>). Finally, we found that the Fisher’s exact test was the most computationally efficient of the three methods (Supplementary Table <xref rid="MOESM1" ref-type="media">6</xref>). In this setting, the Fisher’s exact test offered a statistically robust and efficient alternative to regression-based approaches, but required careful quality control, case–control harmonization and ancestry pruning before association testing.</p>
  </sec>
  <sec id="Sec5">
    <title>Rare variant collapsing analyses</title>
    <p id="Par15">We also performed gene-level association tests using collapsing analyses. In this approach, the proportion of cases with a qualifying variant was compared with the proportion of controls with a qualifying variant in each gene<sup><xref ref-type="bibr" rid="CR16">16</xref>–<xref ref-type="bibr" rid="CR22">22</xref></sup>. We used 12 different sets of qualifying variant filters (models) to test the association between 18,762 genes and 18,780 phenotypes (Methods; Extended Data Table <xref rid="Tab1" ref-type="table">1</xref>), equating to 4.2 billion tests. The models included ten dominant models, one recessive model and one synonymous variant model that served as an empirical negative control (Methods).</p>
    <p id="Par16">Defining a significance threshold posed a challenge due to strong correlation between the 12 models and among the assessed phenotypes. To avoid false claims, we defined two null distributions: an empirical null distribution using the synonymous collapsing model and an <italic>n</italic>-of-1 permutation-based null distribution. These approaches independently converged on a study-wide significance threshold of <italic>P</italic> ≤ 2 × 10<sup>−9</sup> (Methods).</p>
    <p id="Par17">We identified 936 significant gene–phenotype relationships for binary traits and 767 for quantitative traits (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>, Extended Data Fig. <xref rid="Fig6" ref-type="fig">3</xref>, Supplementary Table <xref rid="MOESM3" ref-type="media">8</xref>). These associations were enriched for FDA-approved drugs (binary odds ratio (OR): 7.38 (95% CI: 3.71–13.59), <italic>P</italic> = 1.46 × 10<sup>−7</sup>; quantitative OR: 3.71 (95% CI: 2.23–5.74), <italic>P</italic> = 7.04 × 10<sup>−9</sup>) (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>, Extended Data Fig. <xref rid="Fig7" ref-type="fig">4</xref>; Methods) and spanned most disease areas and disease-relevant biomarkers (Fig. <xref rid="Fig2" ref-type="fig">2c, d</xref>). Many signals were of large effect, with a median OR of 12.4 for binary traits and a median absolute beta of 0.35 for quantitative traits. We also detected several significant genes with putatively protective PTVs, including <italic>APOB</italic> and <italic>PCSK9</italic> (Supplementary Table <xref rid="MOESM1" ref-type="media">9</xref>). The median genomic inflation factor (λ) was 1.002 for binary traits (range: 0.71–1.35) and 1.010 for quantitative traits (range: 0.88–1.37) (Extended Data Fig. <xref rid="Fig8" ref-type="fig">5a</xref>). Only 0.76% of the associations from the 191,037 non-recessive collapsing analyses were outside the 0.9–1.1 λ range. Our tests were thus highly robust to systematic bias and other sources of inflation. Collectively, these findings provide biological insight into common diseases and substrates for future therapeutic development opportunities.<fig id="Fig2"><label>Fig. 2</label><caption><title>Summary of gene-level collapsing analysis results.</title><p><bold>a</bold>, Gene–phenotype associations for binary traits. For gene–phenotype associations that appear in multiple collapsing models, we display only the association with the strongest effect size. The dashed line represents the genome-wide significant <italic>P</italic> value threshold (2 × 10<sup>−9</sup>). The <italic>y</italic> axis is capped at −log<sub>10</sub>(<italic>P</italic>) = 50 and only associations with <italic>P</italic> &lt; 10<sup>−5</sup> were plotted (<italic>n</italic> = 94,208). <bold>b</bold>, Enrichment of FDA-approved drug targets<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup> among significant binary traits, quantitative traits, OMIM genes and GWAS signals. <italic>P</italic> values were generated via two-sided Fisher’s exact test (*<italic>P</italic> &lt; 10<sup>−5</sup>, **<italic>P</italic> &lt; 10<sup>−20</sup>, ***<italic>P</italic> &lt; 10<sup>−70</sup>). Exact statistics: binary odds ratio (OR) = 7.38, 95% CI: 3.71–13.59, <italic>P</italic> = 1.5 × 10<sup>−7</sup>; quantitative OR = 3.71, 95% CI: 2.28–5.76, <italic>P</italic> = 4.5 × 10<sup>−7</sup>; OMIM OR = 5.95, 95% CI: 4.90–7.23, <italic>P</italic> = 1.1 × 10<sup>−75</sup>; GWAS OR = 2.68, 95% CI: 2.12–3.32, <italic>P</italic> = 3.6 × 10<sup>−23</sup>). Error bars represent 95% CIs. Contingency tables were created using each of the binary (<italic>n</italic> = 195), quantitative (<italic>n</italic> = 395), OMIM (<italic>n</italic> = 3,875) and GWAS (<italic>n</italic> = 10,692) categories, alongside approved targets from Informa Pharmaprojects (<italic>n</italic> = 463). <italic>P</italic> values were generated via a two-tailed Fisher’s exact test. <bold>c</bold>, Effect sizes for select gene associations per disease area. Genes with the highest OR for a chapter or with OR &gt; 100 are labelled. <bold>d</bold>, Illustration of large effect gene–phenotype associations for select disease-related quantitative traits. FEV1/FVC, forced expiratory volume in 1 s/forced vital capacity ratio; HDL, high-density lipoprotein; LDL, low-density lipoprotein. Dashed line corresponds to a beta of 0.</p></caption><graphic xlink:href="41586_2021_3855_Fig2_HTML" id="d33e1114"/></fig></p>
    <p id="Par18">Collapsing models focused on PTVs explained 80% of binary and 55% of quantitative associations. Remaining signals emerged from models that included missense variants. While these results confirm the importance of PTVs, they also emphasize the role of other forms of variation in human disease. We found that using the missense tolerance ratio (MTR) to retain missense variants only in constrained genic sub-regions improved the signal-to-noise ratio. Specifically, 15% (133 of 878) of significant relationships detected via the three MTR-informed models were not detected in analogous models that did not incorporate MTR<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. Moreover, for phenotype associations where both MTR and non-MTR versions of a model achieved significance, effect sizes were significantly higher in the MTR-informed versions (Mann–Whitney test <italic>P</italic> = 0.006; Supplementary Fig. <xref rid="MOESM1" ref-type="media">3</xref>). Thus, MTR appears to effectively prioritize putatively functional missense variation in collapsing analyses of complex disease.</p>
    <p id="Par19">Most binary phenotype associations were supported by OMIM or were annotated as pathogenic/likely pathogenic in ClinVar (88.6%), indicating that we robustly captured high-confidence signals (Supplementary Table <xref rid="MOESM3" ref-type="media">10</xref>). However, we also identified rare variant associations with phenotypes beyond those reported in OMIM (Supplementary Table <xref rid="MOESM3" ref-type="media">10</xref>). For example, 12.1% of the European cohort carried at least one of the 373 distinct filaggrin (<italic>FLG</italic>) PTVs identified. These individuals had a significantly higher risk of well-known associations, including dermatitis (<italic>P</italic> = 5.1 × 10<sup>−95</sup>; OR: 1.96 (95% CI: 1.84–2.08)) and asthma (<italic>P</italic> = 3.1 × 10<sup>−32</sup>; OR: 1.24 (95% CI: 1.19–1.28))<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>, but were also at risk of under-recognized associations, such as melanoma (<italic>P</italic> = 4.7 × 10<sup>−13</sup>; OR: 1.21 (95% CI: 1.15–1.27))<sup><xref ref-type="bibr" rid="CR37">37</xref></sup> and basal cell carcinoma (<italic>P</italic> = 9.9 × 10<sup>−10</sup>; OR: 1.19 (95% CI: 1.12–1.25))<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. Concomitant increases in the levels of vitamin D (<italic>P</italic> = 2.3 × 10<sup>−131</sup>; β: 0.15 (95% CI: 0.14–0.16))<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> suggest that the increased risk of skin cancer may be attributable to increased sensitivity to ultraviolet B radiation. This interrogation offers one example of how this phenome-wide resource can uncover a wide spectrum of phenotypes associated with rare variation in any protein-coding gene.</p>
    <p id="Par20">Although our pipeline was tuned for detecting germline variants, we identified seven genes that were significantly associated with haematological malignancies, driven by qualifying variants that appeared to be somatic (Supplementary Tables <xref rid="MOESM1" ref-type="media">11</xref>, <xref rid="MOESM3" ref-type="media">12</xref>, Supplementary Fig. <xref rid="MOESM1" ref-type="media">4</xref>). This supports the potential of blood-based sequencing to yield insight into blood cancer genomes via incidentally detected somatic variants<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>.</p>
    <p id="Par21">Compared with two smaller UKB PheWAS studies<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>, we observed a 1.2-fold and 5.6-fold increase, respectively, in statistically significant gene–trait associations using the same first tranche of 50K UKB data, attributable to both the depth of outcomes studied and differences in methodologies (Extended Data Fig. <xref rid="Fig8" ref-type="fig">5b</xref>). Increasing the cohort size from 50,000 to the current full dataset led to an 18-fold increase in statistically significant gene–trait associations using our collapsing method (Extended Data Fig. <xref rid="Fig8" ref-type="fig">5c</xref>). Incorporating updated phenotypic data from the July 2020 release resulted in a 24-fold increase in significant associations compared with the 50K data (Extended Data Fig. <xref rid="Fig8" ref-type="fig">5c</xref>).</p>
    <p id="Par22">Among significant collapsing analysis signals, only 17% (125 of 724) of binary associations and 58% (446 of 767) of quantitative associations were detectable via ExWAS (Supplementary Table <xref rid="MOESM1" ref-type="media">13A</xref>). Conversely, most rare PTV ExWAS associations were detected via collapsing analyses, although the rates were lower for rare missense variants (Supplementary Table <xref rid="MOESM1" ref-type="media">13B</xref>). Thus, collapsing analyses can identify rare variant associations that are currently undetectable via single-variant-based approaches (Supplementary Table <xref rid="MOESM3" ref-type="media">14</xref>).</p>
  </sec>
  <sec id="Sec6">
    <title>Pan-ancestry collapsing analysis</title>
    <p id="Par23">The inclusion of individuals from non-European ancestries in genetic analyses is crucial for health-care equity and genetic discovery<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. Therefore, we performed additional collapsing analyses for each major non-European ancestral group (that is, South Asian (<italic>n</italic> = 5,714), African (<italic>n</italic> = 4,744) and East Asian (<italic>n</italic> = 1,475)). We limited each PheWAS to binary traits with at least five cases in the population and quantitative traits with at least five qualifying variants carriers (Supplementary Table <xref rid="MOESM3" ref-type="media">1</xref>).</p>
    <p id="Par24">The only study-wide significant (<italic>P</italic> ≤ 2 × 10<sup>−9</sup>) binary trait association among the non-European populations was between PTVs in <italic>HBB</italic> and thalassaemia in individuals of South Asian ancestry (<italic>P</italic> = 2.7 × 10<sup>−46</sup>; OR = 176.4 (95% CI: 84.1–369.7)) (Supplementary Table <xref rid="MOESM3" ref-type="media">15</xref>). We next applied the Cochran–Mantel–Haenszel test to combine the results of the binary trait collapsing analysis across all four studied ancestral groups, including the European population (Methods). This pan-ancestry PheWAS identified 26 unique study-wide significant gene–phenotype associations that were not significant in the European analyses (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>, Extended Data Fig. <xref rid="Fig9" ref-type="fig">6a</xref>, Supplementary Table <xref rid="MOESM3" ref-type="media">16</xref>). Conversely, 20 gene–phenotype associations that were significant in the European analyses did not reach the study-wide significance threshold in the pan-ancestry analysis.<fig id="Fig3"><label>Fig. 3</label><caption><title>Pan-ancestry collapsing analysis.</title><p><bold>a</bold>, <bold>b</bold>, The change in Phred scores between the pan-ancestry and European-only analyses for 46,769 binary associations (<bold>a</bold>) and 39,541 quantitative associations (<bold>b</bold>) stratified by chapter. For gene–phenotype associations that appear in multiple collapsing models, we display only those with the lowest <italic>P</italic> value. The green dots indicate associations that were not significant in the European analysis but were significant in the combined analysis. The orange dots represent associations that were originally significant in the European-only analysis but became not significant in the combined analysis. In both figures, the <italic>y</italic> axis is capped at ΔPhred = 40 (equivalent to a <italic>P</italic> value change of 0.0001).</p></caption><graphic xlink:href="41586_2021_3855_Fig3_HTML" id="d33e1302"/></fig></p>
    <p id="Par25">We analysed 1,419 quantitative traits in a linear regression model including individuals of all major ancestral groups, including Europeans (Supplementary Table <xref rid="MOESM3" ref-type="media">1</xref>). This model included categorical ancestral groups, the top five ancestry principal components, age and sex as covariates (Methods). We identified 59 significant gene–quantitative trait associations that were originally not significant in the European analyses (Fig. <xref rid="Fig3" ref-type="fig">3b</xref>, Extended Data Fig. <xref rid="Fig9" ref-type="fig">6b</xref>). These included associations between rare variants in <italic>OCA2</italic> and a younger age of wearing glasses (<italic>P</italic> = 4.7 × 10<sup>−10</sup>; β: −0.45 (95% CI: −0.60 to −0.31)), <italic>ASGR1</italic> and reduced low-density lipoprotein cholesterol (<italic>P</italic> = 1.7 × 10<sup>−9</sup>; β: −0.26 (95% CI: −0.34 to −0.17)), and others (Supplementary Table <xref rid="MOESM3" ref-type="media">17</xref>). In addition, 46 unique associations between genes and quantitative traits, originally significant in the European analyses, were not significant in the combined analysis.</p>
  </sec>
  <sec id="Sec7" sec-type="discussion">
    <title>Discussion</title>
    <p id="Par26">We performed a PheWAS using exome sequences of 269,171 UKB participants of European ancestry combined with records of 18,780 phenotypes, followed by a pan-ancestry analysis that incorporated an additional 11,933 UKB participants of African, East Asian and South Asian ancestries. In total, we identified 46,837 variant-level and 1,703 gene-level statistically significant relationships. Many associations were previously known, but others were either new or associated with phenotype expansions. We also found that these associations were significantly enriched for targets of US Food and Drug Administration (FDA)-approved drugs, reinforcing the importance of human genetics in target identification. When followed up with functional investigation to understand biological mechanisms, these results can help to improve the efficiency of pharmaceutical pipelines, contribute towards safety assessments and reveal repositioning opportunities<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR42">42</xref></sup>.</p>
    <p id="Par27">Our variant-level association tests detected rare variant associations that are not frequent enough to be captured by microarray-based studies (that is, as rare as MAF = 0.0012%). Our gene-level collapsing analyses evaluated the aggregate effect of private-to-rare functional variants, 83% of which were not detected in single-variant tests for binary traits. Among gene-level signals for which an individual variant also achieved significance, we found examples where both common and rare risk variants in these genes contributed to disease burden. This is consistent with previous work demonstrating that common and rare PTVs in <italic>FLG</italic> have similar effect sizes for the risk of early asthma<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>.</p>
    <p id="Par28">We used a Fisher’s exact test framework for our variant-level and gene-level analyses based on previous success with this approach<sup><xref ref-type="bibr" rid="CR16">16</xref>–<xref ref-type="bibr" rid="CR23">23</xref></sup>. Limitations of the Fisher’s test compared with regression-based approaches<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR45">45</xref></sup> include an inability to adjust for covariates. On a subset of traits selected for comparisons, we observed that the Phred scores for significant variants from the Fisher’s exact test, SAIGE SPA and REGENIE 2.0.2 were nearly perfectly correlated (Pearson’s <italic>r</italic> = 0.99). The Fisher’s exact test generated more conservative statistics for rare variants and was associated with increased computational efficiency. Use of the Fisher’s exact test requires extremely careful quality control, case–control harmonization and ancestry pruning. In the absence of these measures, it is crucial to correct for such confounders via a regression-based approach. Future work should focus on in-depth benchmarking for these different methods. Regardless of the approach used, it is essential to define an appropriate study-wide significance threshold, which we addressed using <italic>n</italic>-of-1 permutation and an empirical null distribution using a synonymous negative control model.</p>
    <p id="Par29">The predominant representation of European ancestry in human genomics has negative ethical and clinical consequences<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR41">41</xref></sup>. Smaller sample sizes limited our ability to detect many associations among individual non-European populations. Performing a combined pan-ancestry PheWAS bolstered the association signal for several binary and quantitative traits. Altogether, these results emphasize the need to establish more diverse biobanks.</p>
    <p id="Par30">The UKB has set an excellent standard for linking genomic and phenotypic data and its dynamic nature will facilitate new opportunities for genetic discovery. In future studies, phenotypes may be refined through combining binary, phenotypic and temporal data. The results of this PheWAS are publicly available (<ext-link ext-link-type="uri" xlink:href="http://azphewas.com/">http://azphewas.com/</ext-link>), which we anticipate will help to elucidate disease mechanisms, identify phenotypic expansions and enable the development of human genetically validated drugs.</p>
  </sec>
  <sec id="Sec8" sec-type="materials|methods">
    <title>Methods</title>
    <sec id="Sec9">
      <title>UKB resource</title>
      <p id="Par31">The UKB is a prospective study of approximately 500,000 participants 40–69 years of age at recruitment. Participants were recruited in the UK between 2006 and 2010 and are continuously followed<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. The average age at recruitment for sequenced individuals was 56.5 years and 54% of the sequenced cohort comprises those of female sex. Participant data include health records that are periodically updated by the UKB, self-reported survey information, linkage to death and cancer registries, collection of urine and blood biomarkers, imaging data, accelerometer data and various other phenotypic end points<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. All study participants provided informed consent.</p>
    </sec>
    <sec id="Sec10">
      <title>Phenotypes</title>
      <p id="Par32">We studied two main phenotypic categories: binary and quantitative traits taken from the February 2020 data release that was accessed on 27 March 2020 as part of UKB application 26041. To parse the UKB phenotypic data, we developed a modified version of the PHESANT package, which can be located at <ext-link ext-link-type="uri" xlink:href="https://github.com/astrazeneca-cgr-publications/PEACOK">https://github.com/astrazeneca-cgr-publications/PEACOK</ext-link>. The adopted parameters are available in Supplementary Methods and have been previously introduced in PHESANT (<ext-link ext-link-type="uri" xlink:href="https://github.com/MRCIEU/PHESANT">https://github.com/MRCIEU/PHESANT</ext-link>)<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>.</p>
      <p id="Par33">The PEACOK R package implementation focuses on separating phenotype matrix generation from statistical association tests. It also allows statistical tests to be performed separately on different computing environments, such as on a high-performance computing cluster or an AWS Batch environment. This package introduces additional functionalities, including the ability to generate phenotypes for every node from a tree-like UKB data code (for example, an ICD-10 code) and to run logistic regression on a binary phenotype with covariates. Various downstream analysis and summarization were performed using R v3.4.3 <ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org">https://cran.r-project.org</ext-link>. R libraries data.table (v1.12.8; <ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=data.table">https://CRAN.R-project.org/package=data.table</ext-link>), MASS (7.3-51.6; <ext-link ext-link-type="uri" xlink:href="https://www.stats.ox.ac.uk/pub/MASS4/">https://www.stats.ox.ac.uk/pub/MASS4/</ext-link>), tidyr (1.1.0; <ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=tidyr">https://CRAN.R-project.org/package=tidyr</ext-link>) and dplyr (1.0.0; <ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=dplyr">https://CRAN.R-project.org/package=dplyr</ext-link>) were also used.</p>
      <p id="Par34">In total, 44 UKB paths were represented for the binary traits and 49 for the quantitative traits. For UKB tree fields, such as the ICD-10 hospital admissions (field 41202), we studied each leaf individually and studied each subsequent higher-level groupings up to the ICD-10 root chapter as separate phenotypic entities. Furthermore, for the tree-related fields (fields: 20001, 20002, 40001, 40002, 40006 and 41202), we restricted controls to participants who did not have a positive diagnosis for any phenotype contained within the corresponding chapter to reduce potential contamination due to genetically related diagnoses. A minimum of 30 cases were required for a binary trait to be studied.</p>
      <p id="Par35">In addition to studying UKB algorithmically defined outcomes, we constructed a union phenotype for each ICD-10 phenotype. These union phenotypes are denoted by a ‘Union’ prefix and the applied mappings are available in Supplementary Table <xref rid="MOESM3" ref-type="media">1</xref>.</p>
      <p id="Par36">In total, we studied 17,361 binary and 1,419 quantitative phenotypes. For all binary phenotypes, we matched controls by sex when the percentage of female cases was significantly different (Fisher’s exact two-sided <italic>P</italic> &lt; 0.05) from the percentage of available female controls. This included sex-specific traits in which, by design, all controls would be same sex as cases. As a result, 10,531 (60.7%) of the binary phenotypes required down sampling of controls to match the case female percentage (Supplementary Table <xref rid="MOESM3" ref-type="media">1</xref>). Finally, to allow for more compartmentalized ICD-10 chapter-based analyses, all 18,780 binary and quantitative trait phenotypes were mapped to a single ICD-10 chapter including manual mapping for the non-ICD-10 phenotypes. Chapter mappings are provided in Supplementary Table <xref rid="MOESM3" ref-type="media">1</xref>. It is acknowledged that chapter mapping may have the greatest utility for diagnostic, rather than procedural, ICD-10 codes. For procedural codes, genetic associations could be incorrectly interpreted if chapter mappings are relied on. For example, surgical procedures commonly performed for patients with cancer are categorized within the dermatology chapter. Genetic associations reported for these procedures would be categorized within the dermatology chapter, but the underlying disease process is instead most probably reflective of an oncological aetiology.</p>
      <p id="Par37">We subsequently re-analysed the 300Kv1 cohort using the updated Hospital Episode Statistic (HES) and death registry data as released ad hoc by the UKB on July 2020. Among Data-Field 41270 of primary and secondary inpatient diagnoses that contribute to the Union phenotypes, we found on average a 38.1% increase in the number of cases when comparing the April 2017 refresh to the July 2020 refresh. Throughout this article, we adopt the July 2020 refresh data as the default analysis dataset and refer to this update as the ‘300Kv2’ dataset. The effect on case numbers before and after updating to this release are documented in Supplementary Table <xref rid="MOESM3" ref-type="media">1</xref>.</p>
    </sec>
    <sec id="Sec11">
      <title>Sequencing</title>
      <p id="Par38">Whole-exome sequencing data for UKB participants were generated at the Regeneron Genetics Center (RGC) as part of a pre-competitive data generation collaboration between AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen, Bristol-Myers Squibb, Pfizer, Regeneron and Takeda with the UKB<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Genomic DNA underwent paired-end 75-bp whole-exome sequencing at Regeneron Pharmaceuticals using the IDT xGen v1 capture kit on the NovaSeq6000 platform. Conversion of sequencing data in BCL format to FASTQ format and the assignments of paired-end sequence reads to samples were based on 10-base barcodes, using bcl2fastq v2.19.0. Exome sequences from 302,355 UKB participants were made available to the Exome Sequencing consortium in December 2019. Initial quality control was performed by Regeneron and included sex discordance, contamination, unresolved duplicate sequences and discordance with microarray genotyping data checks<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>.</p>
    </sec>
    <sec id="Sec12">
      <title>AstraZeneca Centre for Genomics Research (CGR) bioinformatics pipeline</title>
      <p id="Par39">The 302,355 UKB exome sequences were processed at AstraZeneca from their unaligned FASTQ state. A custom-built Amazon Web Services (AWS) cloud compute platform running Illumina DRAGEN Bio-IT Platform Germline Pipeline v3.0.7 was used to align the reads to the GRCh38 genome reference and perform single-nucleotide variant (SNV) and insertion and deletion (indel) calling. SNVs and indels were annotated using SnpEFF v4.3<sup><xref ref-type="bibr" rid="CR48">48</xref></sup> against Ensembl Build 38.92<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>. We further annotated all variants with their genome Aggregation Database (gnomAD) MAFs (gnomAD v2.1.1 mapped to GRCh38)<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. We also annotated missense variants with MTR and REVEL scores<sup><xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup>.</p>
    </sec>
    <sec id="Sec13">
      <title>Additional quality control</title>
      <p id="Par40">To complement the quality control performed by Regeneron Pharmaceuticals, we passed the 302,355 sequences through our internal bioinformatics pipeline. In addition to what had already been flagged for quality control, we excluded from our analyses 106 (0.035%) sequences that achieved a VerifyBAMID freemix (contamination) level of more than 4%<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>, and an additional five sequences (0.002%) where less than 94.5% of the consensus coding sequence (CCDS release 22) achieved a minimum of tenfold read depth<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>.</p>
      <p id="Par41">To mitigate a possible increase of variance estimates due to relatedness, we sought to remove related individuals from our analyses. Using exome sequence-derived genotypes for 43,889 biallelic autosomal SNVs located in coding regions as input to the kinship algorithm included in KING v2.2.3<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>, we generated pairwise kinship coefficients for all remaining samples.</p>
      <p id="Par42">We used the ukb_gen_samples_to_remove() function from the R package ukbtools v0.11.3<sup><xref ref-type="bibr" rid="CR54">54</xref></sup> to choose a subset of individuals within which no pair had a kinship coefficient exceeding 0.0884, equivalent of up to third-degree relatives. For each related pair, this function removes whichever member has the highest number or relatives above the provided threshold, resulting in a maximal set. Through this process, an additional 14,326 (4.74%) sequences were removed from downstream analyses.</p>
      <p id="Par43">After the above quality control steps, there remained 287,917 (95.2%) predominantly unrelated sequences of any genetic ancestry that were available for analyses presented in this work.</p>
    </sec>
    <sec id="Sec14">
      <title>Genetic ancestry</title>
      <p id="Par44">For most of the case–control cohort analyses, we restricted the statistical tests to include a homogeneous European genetic ancestry test cohort. We predicted genetic ancestries from the exome data using peddy v0.4.2 with the ancestry labelled 1,000 Genomes Project as reference. <sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. Of the 287,917 UKB sequences, 18,212 (6.3%) had a Pr(European) ancestry prediction of less than 0.99. Focusing on the remaining 269,706 UKB participants, we further restricted the European ancestry cohort to those within ±4 s.d. across the top four principal component means. This resulted in the exclusion of an additional 535 (0.2%) outlier participants. In total, there were 269,171 predominantly unrelated participants of European ancestry who were included in our European case–control analyses. We also used peddy-derived ancestry predictions to perform case–control PheWAS within non-European populations where there were at least 1,000 exome-sequenced individuals available (see the section ‘Collapsing analyses’). Through this step, we identified and used 4,744 (Pr(African) &gt; 0.95), 1,475 (Pr(East Asian) &gt; 0.95) and 5,714 (Pr(South Asian) &gt; 0.95) UKB participants for ancestry-independent collapsing analyses.</p>
    </sec>
    <sec id="Sec15">
      <title>ExWAS analyses</title>
      <p id="Par45">The contribution of rare variants to common disease has, until recently, only been assessed for a subset of complex traits. The gnomAD, which includes exome and genome sequencing data of 141,456 individuals, constitutes the largest publicly available next-generation sequencing resource to date<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. While this resource has undeniably transformed our ability to interpret rare variants and discover disease-associated genes, it is unsuited to the systematic assessment of the contribution of rare variation to human disease as it lacks linked phenotypic data.</p>
      <p id="Par46">We tested the 2,108,983 variants identified in at least six individuals from the 269,171 predominantly unrelated European ancestry UKB exomes. Variants were required to pass the following quality control criteria: minimum coverage 10X; percent of alternate reads in heterozygous variants ≥ 0.2; binomial test of alternate allele proportion departure from 50% in heterozygous state <italic>P</italic> &gt; 1 × 10<sup>−6</sup>; genotype quality score (GQ) ≥ 20; Fisher’s strand bias score (FS) ≤ 200 (indels) ≤ 60 (SNVs); mapping quality score (MQ) ≥ 40; quality score (QUAL) ≥ 30; read position rank sum score (RPRS) ≥ −2; mapping quality rank sum score (MQRS) ≥ −8; DRAGEN variant status = PASS; variant site is not missing (that is, less than 10X coverage) in 10% or more of sequences; the variant did not fail any of the aforementioned quality control in 5% or more of sequences; the variant site achieved tenfold coverage in 30% or more of gnomAD exomes, and if the variant was observed in gnomAD exomes, 50% or more of the time those variant calls passed the gnomAD quality control filters (gnomAD exome AC/AC_raw ≥ 50%).</p>
      <p id="Par47">Variant-level <italic>P</italic> values were generated adopting a Fisher’s exact two-sided test. Three distinct genetic models were studied for binary traits: allelic (A versus B allele), dominant (AA + AB versus BB) and recessive (AA versus AB + BB), where A denotes the alternative allele and B denotes the reference allele. For quantitative traits, we adopted a linear regression (correcting for age, sex and age × sex) and replaced the allelic model with a genotypic (AA versus AB versus BB) test. For ExWAS analysis, we used a significance cut-off of <italic>P</italic> ≤ 2 × 10<sup>−9</sup>. To support the use of this threshold in this study, we performed an <italic>n</italic>-of-1 permutation on the binary and quantitative trait dominant model ExWAS. Only 18 of 38.7 billion permuted tests had <italic>P</italic> ≤ 2 × 10<sup>−9</sup>, and 58 of 38.7 billion permuted tests had <italic>P</italic> values less than a more liberal cut-off of 1 × 10<sup>−8</sup> (Supplementary Tables <xref rid="MOESM1" ref-type="media">18</xref>, <xref rid="MOESM3" ref-type="media">19</xref>). At this conservative <italic>P</italic> ≤ 2 × 10<sup>−9</sup> threshold, the expected number of ExWAS PheWAS false positives is 18 out of the 46,947 observed significant associations.</p>
    </sec>
    <sec id="Sec16">
      <title>Collapsing analyses</title>
      <p id="Par48">To perform collapsing analyses, we aggregate variants within each gene that fit a given set of criteria, identified as qualifying variants<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Overall, we performed 11 non-synonymous collapsing analyses, including 10 dominant and one recessive model, plus an additional synonymous variant model as an empirical negative control. In each model, for each gene, the proportion of cases was compared to the proportion of controls among individuals carrying one or more qualifying variants in that gene. The exception is the recessive model, where a participant must have two qualifying alleles, either in homozygous or potential compound heterozygous form. Hemizygous genotypes for the X chromosome were also qualified for the recessive model. The qualifying variant criteria for each collapsing analysis model are in Extended Data Table <xref rid="Tab1" ref-type="table">1</xref>. These models were designed to collectively capture a wide range of genetic architectures. They vary in terms of allele frequency (from private up to a maximum of 5%), predicted consequence (for example, PTV or missense), and REVEL and MTR scores. On the basis of SnpEff annotations, we defined synonymous variants as those annotated as ‘synonymous_variant’. We defined PTVs as variants annotated as exon_loss_variant, frameshift_variant, start_lost, stop_gained, stop_lost, splice_acceptor_variant, splice_donor_variant, gene_fusion, bidirectional_gene_fusion, rare_amino_acid_variant, and transcript_ablation. We defined missense as: missense_variant_splice_region_variant, and missense_variant. Non-synonymous variants included: exon_loss_variant, frameshift_variant, start_lost, stop_gained, stop_lost, splice_acceptor_variant, splice_donor_variant, gene_fusion, bidirectional_gene_fusion, rare_amino_acid_variant, transcript_ablation, conservative_inframe_deletion, conservative_inframe_insertion, disruptive_inframe_insertion, disruptive_inframe_deletion, missense_variant_splice_region_variant, missense_variant, and protein_altering_variant.</p>
      <p id="Par49">Collapsing analysis <italic>P</italic> values were generated by using a Fisher’s exact two-sided test. For quantitative traits, we used a linear regression, correcting for age, sex and age × sex.</p>
      <p id="Par50">For all models (Extended Data Table <xref rid="Tab1" ref-type="table">1</xref>), we applied the following quality control filters: minimum coverage 10X; annotation in CCDS transcripts (release 22; approximately 34 Mb); at most 80% alternate reads in homozygous genotypes; percent of alternate reads in heterozygous variants ≥ 0.25 and ≤ 0.8; binomial test of alternate allele proportion departure from 50% in heterozygous state <italic>P</italic> &gt; 1 × 10<sup>−6</sup>; GQ ≥ 20; FS ≤ 200 (indels) ≤ 60 (SNVs); MQ ≥ 40; QUAL ≥ 30; read position rank sum score ≥ −2; MQRS ≥ −8; DRAGEN variant status = PASS; the variant site achieved tenfold coverage in ≥ 25% of gnomAD exomes, and if the variant was observed in gnomAD exomes, the variant achieved exome z-score ≥ −2.0 and exome MQ ≥ 30.</p>
      <p id="Par51">To quantify how well a protein-coding gene is represented across all individuals by the exome sequence data, we estimated informativeness statistics for each studied gene on the basis of sequencing coverage across the available exomes (Supplementary Methods, Supplementary Table <xref rid="MOESM3" ref-type="media">24</xref>). Moreover, we created dummy phenotypes to correspond to each of the four exome sequence delivery batches to identify and exclude from analyses genes and variants that reflected sequencing batch effects; we provide these as a cautionary list resource for other UKB exome researchers (Supplementary Methods, Supplementary Tables <xref rid="MOESM1" ref-type="media">25</xref>–<xref rid="MOESM1" ref-type="media">27</xref>).</p>
      <p id="Par52">For the pan-ancestry analysis, a Cochran–Mantel–Haenszel test was performed to generate a combined 2 × 2 × <italic>N</italic> stratified <italic>P</italic> value, with <italic>N</italic> representing up to all four genetic ancestry groups. This was performed for 4,836 binary phenotypes where one of the three non-European ancestries had five or more cases and for all quantitative traits. For the quantitative traits, we used a linear regression model that included the following covariates: categorical ancestry (European, African, East Asian or South Asian), the top five ancestry principal components, age and sex.</p>
    </sec>
    <sec id="Sec17">
      <title>Compute processing times</title>
      <p id="Par53">Our end-to-end (CRAM → FASTQ → BAM → VCF) processing of the 302,355 UKB exomes was achieved at an average rate of 1,600 exomes per hour, consuming a total of 52,000 hours of CPU time running on Linux servers with FPGA acceleration.</p>
      <p id="Par54">Regarding our collapsing PheWAS analyses, construction of the full set of genotype and phenotype matrices took 13,000 and 30 CPU hours to compile, respectively. The preprocessing steps such as rebalancing sex-specific case–control ratios are incorporated in the phenotype matrix construction time. Subsequently, the approximately 4.5 billion collapsing analysis statistical tests were calculated in 19,000 CPU hours. In wall-clock hours, this took 30 h to generate all the collapsing and phenotype matrices. Once the intermediate files were ready, the roughly 4.5 billion collapsing statistical tests took 8 h to complete.</p>
      <p id="Par55">Regarding our variant-level ExWAS, upon construction of our variant matrices, which took 2,500 CPU hours to compile, all 108 billion statistical tests were calculated in 855,000 CPU hours. In wall-clock hours, this took 37 h to generate the variant matrices. Once these intermediate files were ready, the approximately 108 billion ExWAS statistical tests took 27 h for binary traits and 11 h for quantitative traits.</p>
    </sec>
    <sec id="Sec18">
      <title>Defining the study-wide significant cut-offs for collapsing analyses</title>
      <p id="Par56">Bonferroni correction for multiple testing was inappropriate to use in this study given the high degree of correlation among the studied phenotypes and the level of similarity among the multiple collapsing models. Thus, we took two approaches to define more appropriate study-wide significance thresholds for the gene-based collapsing PheWAS.</p>
      <p id="Par57">We used a synonymous collapsing analysis model as an empirical negative control. Here it is expected that synonymous variants will generally not significantly contribute to disease risk and could thus act as a useful empirical negative control for study-wide <italic>P</italic> value thresholding. Across the 17,361 studied binary phenotypes and 18,762 studied genes, we observed a distribution of 325,727,082 Fisher’s exact test statistics corresponding to the synonymous collapsing model. At the tail of this distribution for binary traits, we identified two genuine relationships: <italic>IGLL5</italic> synonymous variants enriched among ‘Union#C911#C91.1 chronic lymphocytic leukaemia’ (<italic>P</italic> = 2.5 × 10<sup>−11</sup>) and its parent node ‘Union#C91#C91 lymphoid leukaemia’ (<italic>P</italic> = 1.2 × 10<sup>−10</sup>). Following this, we observed a tail of <italic>P</italic> values beginning from <italic>P</italic> = 2.2 × 10<sup>−8</sup> (Supplementary Table <xref rid="MOESM3" ref-type="media">20</xref>). Similarly, for the 1,419 quantitative phenotypes, we observed a distribution of 26,623,278 Fisher’s exact test statistics corresponding to the synonymous collapsing model. At the tail of this distribution, we identified two genuine relationships: <italic>MACROD1</italic> synonymous variants correlating with decreased levels of ‘Urate’ (<italic>P</italic> = 2.8 × 10<sup>−30</sup>)<sup><xref ref-type="bibr" rid="CR56">56</xref></sup> and <italic>ALPL</italic> synonymous variants correlating with decreased levels of ‘alkaline phosphatase’ (<italic>P</italic> = 9.3 × 10<sup>−9</sup>)<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>. Following this, we saw a tail of <italic>P</italic> values beginning from <italic>P</italic> = 5.2 × 10<sup>−8</sup> (Supplementary Table <xref rid="MOESM3" ref-type="media">20</xref>).</p>
      <p id="Par58">With this magnitude of test statistics generated in the PheWAS scale, another proposal for <italic>P</italic> value thresholding involves <italic>n</italic>-of-1 permutation<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>. In applying this approach, we shuffled the case–control (or quantitative measurement) labels once for every phenotype while maintaining the participant-genotype structure and across all 11 non-synonymous collapsing models for binary traits (3,582,997,902 tests) and quantitative traits (292,856,058 tests). Reviewing the tails of these two <italic>P</italic> value distributions, the lowest permutation-based <italic>P</italic> value achieved was 1.9 × 10<sup>−9</sup> (binary tests) and 3.2 × 10<sup>−9</sup> (quantitative tests).</p>
      <p id="Par59">Given the scale and correlations among this dataset, we found that both of these approaches provide suitable alternatives to the Bonferroni <italic>P</italic> value threshold, which in this case would be <italic>P</italic> &lt; 1.2 × 10<sup>−11</sup>. Prioritizing the results of the permutation-based approach because it captures the data structure across all our models, we define a conservative study-wide significance cut-off of <italic>P</italic> ≤ 2 × 10<sup>−9</sup> for the non-synonymous collapsing analysis results presented in this paper (Supplementary Tables <xref rid="MOESM3" ref-type="media">20</xref>, <xref rid="MOESM1" ref-type="media">21</xref>). Under this conservative threshold, no positive associations are expected under the null for collapsing analyses.</p>
      <p id="Par60">Finally, for each of the 225,360 exome-wide collapsing analyses comprising the collapsing PheWAS (12 models × (17,361 + 1,419) studied phenotypes), we calculated the lambda genomic inflation factor (<italic>λ</italic>) after excluding genes achieving exome-wide significance <italic>P</italic> &lt; 2.6 × 10<sup>−6</sup> for that phenotype (Supplementary Tables <xref rid="MOESM3" ref-type="media">22</xref>, <xref rid="MOESM1" ref-type="media">23</xref>).</p>
    </sec>
    <sec id="Sec19">
      <title>Collapsing analysis enrichment for approved drug targets</title>
      <p id="Par61">We tested for the enrichment of drug targets among collapsing analysis associations using five publicly available lists: a custom list (<italic>n</italic> = 387; <ext-link ext-link-type="uri" xlink:href="https://raw.githubusercontent.com/ericminikel/drug_target_lof/master/data/drugbank/drug_gene_match.tsv">https://raw.githubusercontent.com/ericminikel/drug_target_lof/master/data/drugbank/drug_gene_match.tsv</ext-link>) that was originally derived from DrugBank<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>, and another four lists<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> that were originally derived from the Informa Pharmaprojects database<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. These four lists included drug targets from their latest stages of clinical trials, labelled as ‘Approved’ (<italic>n</italic> = 2,620), ‘Phase I Clinical Trial’ (<italic>n</italic> = 3,365), ‘Phase II Clinical Trial’ (<italic>n</italic> = 5,479) and ‘Phase III Clinical Trial’ (<italic>n</italic> = 1,233).</p>
      <p id="Par62">For each gene tested in the collapsing analysis, we only retained the most significantly associated phenotype. Distinct gene–phenotype relationships from the collapsing analysis were partitioned into three categories (significant: <italic>P</italic> &lt; 2 × 10<sup>−9</sup> (binary <italic>n</italic> = 82, quantitative <italic>n</italic> = 269); suggestive: 2 × 10<sup>−9</sup> &lt; <italic>P</italic> &lt; 1 × 10<sup>−7</sup> (binary <italic>n</italic> = 113, quantitative <italic>n</italic> = 126); or non-significant: <italic>P</italic> &gt; 1 × 10<sup>−7</sup> (binary <italic>n</italic> = 18,551, quantitative <italic>n</italic> = 18,351)). The relationship between drug target status and gene–phenotype significance was assessed using Fisher’s exact test for each gene list. Specifically, for each of the five lists, we created a contingency table that included the number of significant collapsing analysis genes that intersected with the list and the number of genes that did not intersect with the list out of the list of genes tested in the PheWAS (<italic>n</italic> = 18,762). This was performed for both binary and quantitative traits. We also performed enrichment testing for OMIM<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> genes and GWAS Catalog<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> significant hits (both last accessed on 14 July 2020). We included the most significant associations per gene for the GWAS analysis.</p>
    </sec>
    <sec id="Sec20">
      <title>Ethics reporting</title>
      <p id="Par63">The protocols for UKB are overseen by The UK Biobank Ethics Advisory Committee (EAC); for more information see <ext-link ext-link-type="uri" xlink:href="https://www.ukbiobank.ac.uk/ethics/">https://www.ukbiobank.ac.uk/ethics/</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://www.ukbiobank.ac.uk/wp-content/uploads/2011/05/EGF20082.pdf">https://www.ukbiobank.ac.uk/wp-content/uploads/2011/05/EGF20082.pdf</ext-link>.</p>
    </sec>
    <sec id="Sec21">
      <title>Reporting summary</title>
      <p id="Par64">Further information on research design is available in the <xref rid="MOESM2" ref-type="media">Nature Research Reporting Summary</xref> linked to this paper.</p>
    </sec>
  </sec>
  <sec id="Sec22" sec-type="materials|methods">
    <title>Online content</title>
    <p id="Par65">Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41586-021-03855-y.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <sec id="Sec24">
      <title>Supplementary information</title>
      <p>
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="41586_2021_3855_MOESM1_ESM.docx">
            <label>Supplementary Information</label>
            <caption>
              <p>This file contains Supplementary Methods, Supplementary Figures 1-4, Supplementary Tables 3, 6, 9, 11, 13, 18, 21, 23, 25, and 27, detailed descriptions of Supplementary Datasets, and Supplementary References.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM2">
          <media xlink:href="41586_2021_3855_MOESM2_ESM.pdf">
            <caption>
              <p>Reporting Summary</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM3">
          <media xlink:href="41586_2021_3855_MOESM3_ESM.zip">
            <label>Supplementary Tables</label>
            <caption>
              <p>This file contains Supplementary Tables 1, 2, 4, 5, 7, 8, 10, 12, 14, 15-17, 19, 20, 22, 24, 26, 28 and 29.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM4">
          <media xlink:href="41586_2021_3855_MOESM4_ESM.pdf">
            <caption>
              <p>Peer Review File</p>
            </caption>
          </media>
        </supplementary-material>
      </p>
    </sec>
  </sec>
</body>
<back>
  <app-group>
    <app id="App1">
      <sec id="Sec23">
        <title>Extended data figures and tables</title>
        <p id="Par67">
          <fig id="Fig4">
            <label>Extended Data Fig. 1</label>
            <caption>
              <title>Phenotypic and demographic diversity of the sequenced UK Biobank cohort.</title>
              <p><bold>a</bold>, The percentage of binary union traits assessed in the cohort per disease chapter. <bold>b</bold>, The percentage of quantitative traits assessed in the cohort per chapter. <bold>c</bold>, The median number of cases of European ancestry per binary union phenotype stratified by chapter with interquartile range depicted. The median number of European cases per binary union phenotype was 191 (interquartile range: 72-773). <bold>d</bold>, The median number of participants of European ancestry tested for quantitative traits stratified by chapter with interquartile ranges depicted. The median number of individuals tested for quantitative traits was 13,782 (interquartile range: 13,780-17,795). <bold>e</bold>, Histogram depicting the number of binary union phenotypes per patient. The <italic>x</italic>-axis was capped at 200 for visual clarity. The median number of binary union traits per European participant was 25 (interquartile range: 12-45) of a possible 4,911. <bold>f</bold>, The distribution of represented genetic ancestries in the sequenced cohort. EUR = European, SAS = South Asian, AFR = African, EAS = East Asian, AMR = American. <bold>g</bold>, The distribution of the number of rare (MAF &lt;0.005%) qualifying variants (QVs) in OMIM-derived Mendelian disease genes per ancestral group. Error bars in (<bold>c</bold>, <bold>d</bold>) represent the interquartile range.</p>
            </caption>
            <graphic position="anchor" xlink:href="41586_2021_3855_Fig4_ESM" id="d33e2065"/>
          </fig>
        </p>
        <p id="Par68">
          <fig id="Fig5">
            <label>Extended Data Fig. 2</label>
            <caption>
              <title>Rare PTVs and direction of variant effects.</title>
              <p><bold>a</bold>, The number of genes (<italic>y</italic>-axis) with at least <italic>N</italic> rare (MAF &gt;0.01) protein-truncating variant (PTV) carriers (<italic>x</italic>-axis) in the cohort. Colours correspond to heterozygous (Het), putative compound heterozygous plus homozygous/hemizygous carriers (comp. het), and exclusively homozygous/hemizygous carriers (recessive). <bold>b</bold>, Distribution of the directions of effect for rare (MAF &lt;0.1%) non-synonymous variant associations with quantitative phenotypes. Only phenotypes with at least five significant non-synonymous variant associations (<italic>P</italic> ≤ 2 × 10<sup>−9</sup>) in a given gene were considered.</p>
            </caption>
            <graphic position="anchor" xlink:href="41586_2021_3855_Fig5_ESM" id="d33e2097"/>
          </fig>
        </p>
        <p id="Par69">
          <fig id="Fig6">
            <label>Extended Data Fig. 3</label>
            <caption>
              <title>Quantitative trait collapsing analysis.</title>
              <p>Plot depicting significant gene-phenotype associations for quantitative traits. For gene–phenotype associations that appear in multiple collapsing models, we display only the association with the strongest effect size. The dashed line represents the genome-wide significant p-value threshold (2 × 10<sup>−9</sup>). The plot is capped at -log10(<italic>P</italic>) = 50 and only associations with <italic>P</italic> &lt; 10<sup>-5</sup> are included (<italic>n</italic> = 22,549).</p>
            </caption>
            <graphic position="anchor" xlink:href="41586_2021_3855_Fig6_ESM" id="d33e2122"/>
          </fig>
        </p>
        <p id="Par70">
          <fig id="Fig7">
            <label>Extended Data Fig. 4</label>
            <caption>
              <title>Drug target enrichments.</title>
              <p>Forest plots demonstrating enrichment of drug targets curated in DrugBank and the Informa Pharmaprojects databases among significant (Tier 1) and nearly significant (Tier 2) binary trait associations, quantitative trait associations, OMIM genes, and GWAS signals. P-values were calculated via Fisher’s exact test (two-sided). Error bars represent 95% confidence intervals of the Odds Ratio. The total numbers of genes per category are as follows: DrugBank-derived (<italic>n</italic> = 386); Approved from Informa Pharmaprojects (<italic>n</italic> = 463); Phase III from Informa Pharmaprojects (<italic>n</italic> = 474); Phase II from Informa Pharmaprojects (<italic>n</italic> = 1006); Phase I from Informa Pharmaprojects (<italic>n</italic> = 921); Collapsing – Binary (Tier 1 <italic>n</italic> = 82; Tier 2 <italic>n</italic> = 113); Collapsing - Quantitative (Tier 1 <italic>n</italic> = 269; Tier 2 <italic>n</italic> = 126); OMIM (<italic>n</italic> = 3875); GWAS (Tier 1 <italic>n</italic> = 8975; Tier 2 <italic>n</italic> = 1717).</p>
            </caption>
            <graphic position="anchor" xlink:href="41586_2021_3855_Fig7_ESM" id="d33e2172"/>
          </fig>
        </p>
        <p id="Par71">
          <fig id="Fig8">
            <label>Extended Data Fig. 5</label>
            <caption>
              <title>Collapsing analysis comparisons.</title>
              <p><bold>a</bold>, Distribution of lambda (inflation factor) values across all collapsing models for binary and quantitative traits. <bold>b</bold>, Venn diagram for gene-trait associations identified by three studies using the first tranche of 50K UKB. There are 81 distinct significant gene-trait associations (<italic>P</italic> &lt; 3.4x10<sup>−10</sup>) found among phenotypes that were studied by the three efforts (Supplementary Table <xref rid="MOESM3" ref-type="media">28</xref>). <bold>c</bold>, Percentage of suggestive binary gene-phenotype associations that became significant (sig) (<italic>P</italic> &lt; 2x10<sup>−9</sup>), non-significant (non-sig) (<italic>P</italic> &gt; 1x10<sup>−7</sup>) or remained suggestive (sugg) (2x10<sup>−9</sup> &lt; <italic>P</italic> &lt; 1x10<sup>−7</sup>) with each successive UKB tranche release for binary traits (supplementary methods). 300Kv1 includes phenotypic data released up to April 2017, and 300Kv2 includes additional phenotypic data for the same set of samples released up to July 2020.</p>
            </caption>
            <graphic position="anchor" xlink:href="41586_2021_3855_Fig8_ESM" id="d33e2219"/>
          </fig>
        </p>
        <p id="Par72">
          <fig id="Fig9">
            <label>Extended Data Fig. 6</label>
            <caption>
              <title>Pan-ancestry delta Phred distributions.</title>
              <p><bold>a</bold>, <bold>b</bold>, Distribution of the change between Phred ((-10*log<sub>10</sub>[p-values]) scores from the pan-ancestry collapsing analysis and the European-only collapsing analysis for binary traits (<bold>a</bold>) and quantitative traits (<bold>b</bold>). The <italic>x</italic>-axis in both figures are capped at -50 and +50.</p>
            </caption>
            <graphic position="anchor" xlink:href="41586_2021_3855_Fig9_ESM" id="d33e2247"/>
          </fig>
        </p>
        <p id="Par73">
          <table-wrap id="Tab1">
            <label>Extended Data Table 1</label>
            <caption>
              <p>Collapsing analysis models</p>
            </caption>
            <graphic position="anchor" xlink:href="41586_2021_3855_Tab1_ESM" id="d33e2257">
              <caption>
                <p>Collapsing analysis models</p>
              </caption>
            </graphic>
            <table-wrap-foot>
              <p>“*” reflects the gnomAD global_raw MAF unless otherwise specified. “^” reflects the maximum proportion of UKB exome sequences permitted to either have ≤ 10-fold coverage at variant site or carry a low-confidence variant that did not meet one of the quality-control thresholds applied to collapsing analyses (see <xref rid="Sec8" ref-type="sec">Methods</xref>).</p>
            </table-wrap-foot>
          </table-wrap>
        </p>
      </sec>
    </app>
  </app-group>
  <fn-group>
    <fn>
      <p><bold>Peer review information</bold><italic>Nature</italic> thanks Beryl Cummings, Dean Sheppard, David van Heel and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.</p>
    </fn>
    <fn>
      <p><bold>Publisher’s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
    <fn>
      <p>These authors contributed equally: Quanli Wang, Ryan S. Dhindsa, Keren Carss</p>
    </fn>
    <fn>
      <p>A list of authors and their affiliations appears at the end of the paper</p>
    </fn>
  </fn-group>
  <sec>
    <title>Extended data</title>
    <p>is available for this paper at 10.1038/s41586-021-03855-y.</p>
  </sec>
  <sec>
    <title>Supplementary information</title>
    <p>The online version contains supplementary material available at 10.1038/s41586-021-03855-y.</p>
  </sec>
  <ack>
    <title>Acknowledgements</title>
    <p>We thank the participants and investigators in the UKB study who made this work possible (Resource Application Number 26041); the UKB Exome Sequencing Consortium (UKB-ESC) members AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen, Bristol-Myers Squibb, Pfizer, Regeneron and Takeda for funding the generation of the data and Regeneron Genetics Center for completing the sequencing and initial quality control of the exome sequencing data; the AstraZeneca Centre for Genomics Research Analytics and Informatics team for processing and analysis of sequencing data; and M. Hurles and D. Balding for feedback on this manuscript. We acknowledge the participants and investigators of the FinnGen study.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Author contributions</title>
    <p>Q.W., R.S.D. and S.P. designed the study. Q.W., R.S.D., K.C., A.R.H., A.N., I.T., D.V., M.H., S.M., K.R.S. and S.P. performed analyses and statistical interpretation. Q.W., S.V.V.D. and S.W. did the bioinformatics processing. I.T. performed benchmarking with support from Q.W. Q.W., K.C., K.R.S. and S.W. scoped and lead the PheWAS portal development. R.M., A.P., C.H. and S.P. contributed to the organization of the project. Q.W., R.S.D., K.C., A.R.H., A.N., I.T. and S.P. wrote the manuscript. Q.W., R.S.D., K.C., A.R.H., A.N., I.T., D.V., S.V.V.D., A.M., D.M., M.H., S.M., H.O., S.W., K.R.S., R.M., A.P., C.H. and S.P. reviewed the manuscript.</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Data availability</title>
    <p>Association statistics generated in this study are publicly available through our AstraZeneca Centre for Genomics Research (CGR) PheWAS Portal (<ext-link ext-link-type="uri" xlink:href="http://azphewas.com/">http://azphewas.com/</ext-link>). All whole-exome sequencing data described in this paper are publicly available to registered researchers through the UKB data access protocol. Exomes can be found in the UKB showcase portal: <ext-link ext-link-type="uri" xlink:href="https://biobank.ndph.ox.ac.uk/showcase/label.cgi?id=170">https://biobank.ndph.ox.ac.uk/showcase/label.cgi?id=170</ext-link>. Additional information about registration for access to the data is available at <ext-link ext-link-type="uri" xlink:href="http://www.ukbiobank.ac.uk/register-apply/">http://www.ukbiobank.ac.uk/register-apply/</ext-link>. Data for this study were obtained under Resource Application Number 26041.</p>
    <p> A custom list of drug targets from DrugBank is available: <ext-link ext-link-type="uri" xlink:href="https://raw.githubusercontent.com/ericminikel/drug_target_lof/master/data/drugbank/drug_gene_match.tsv">https://raw.githubusercontent.com/ericminikel/drug_target_lof/master/data/drugbank/drug_gene_match.tsv</ext-link>. A Pharmaprojects-based list of drug targets is available: <ext-link ext-link-type="uri" xlink:href="https://raw.githubusercontent.com/AbbVie-ComputationalGenomics/genetic-evidence-approval/master/data/target_indication.tsv">https://raw.githubusercontent.com/AbbVie-ComputationalGenomics/genetic-evidence-approval/master/data/target_indication.tsv</ext-link>.</p>
    <p> We used data from the OMIM (<ext-link ext-link-type="uri" xlink:href="https://www.omim.org">https://www.omim.org</ext-link>)<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>, MTR (<ext-link ext-link-type="uri" xlink:href="http://mtr-viewer.mdhs.unimelb.edu.au">http://mtr-viewer.mdhs.unimelb.edu.au</ext-link>)<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>, REVEL<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>, gnomAD (<ext-link ext-link-type="uri" xlink:href="https://gnomad.broadinstitute.org">https://gnomad.broadinstitute.org</ext-link>)<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>, EBI GWAS Catalog (<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/gwas">https://www.ebi.ac.uk/gwas</ext-link>)<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>, ClinVar (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/clinvar">https://www.ncbi.nlm.nih.gov/clinvar</ext-link>)<sup><xref ref-type="bibr" rid="CR30">30</xref></sup> and FinnGen release r5 (<ext-link ext-link-type="uri" xlink:href="https://www.finngen.fi/en">https://www.finngen.fi/en</ext-link>).</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Code availability</title>
    <p>PheWAS and ExWAS association tests were performed using a custom framework, PEACOK (PEACOK 1.0.7), which is an extension and enhancement of PHESANT. PEACOK 1.0.7 is available on GitHub: <ext-link ext-link-type="uri" xlink:href="https://github.com/astrazeneca-cgr-publications/PEACOK/">https://github.com/astrazeneca-cgr-publications/PEACOK/</ext-link>.</p>
  </notes>
  <notes id="FPar1" notes-type="COI-statement">
    <title>Competing interests</title>
    <p id="Par66">Q.W., R.S.D., K.C., A.R.H., A.N., I.T., D.V., S.V.V.D., A.M., D.M., M.H., S.M., H.O., S.W., K.R.S., R.M., A.P., C.H. and S.P are current employees and/or stockholders of AstraZeneca.</p>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bycroft</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The UK Biobank resource with deep phenotyping and genomic data</article-title>
        <source>Nature</source>
        <year>2018</year>
        <volume>562</volume>
        <fpage>203</fpage>
        <lpage>209</lpage>
        <pub-id pub-id-type="doi">10.1038/s41586-018-0579-z</pub-id>
        <?supplied-pmid 30305743?>
        <pub-id pub-id-type="pmid">30305743</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Szustakowski</surname>
            <given-names>JD</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank</article-title>
        <source>Nat. Genet.</source>
        <year>2021</year>
        <volume>53</volume>
        <fpage>942</fpage>
        <lpage>948</lpage>
        <pub-id pub-id-type="doi">10.1038/s41588-021-00885-0</pub-id>
        <?supplied-pmid 34183854?>
        <pub-id pub-id-type="pmid">34183854</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Plenge</surname>
            <given-names>RM</given-names>
          </name>
          <name>
            <surname>Scolnick</surname>
            <given-names>EM</given-names>
          </name>
          <name>
            <surname>Altshuler</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Validating therapeutic targets through human genetics</article-title>
        <source>Nat. Rev. Drug Discov.</source>
        <year>2013</year>
        <volume>12</volume>
        <fpage>581</fpage>
        <lpage>594</lpage>
        <pub-id pub-id-type="doi">10.1038/nrd4051</pub-id>
        <?supplied-pmid 23868113?>
        <pub-id pub-id-type="pmid">23868113</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ashley</surname>
            <given-names>EA</given-names>
          </name>
        </person-group>
        <article-title>Towards precision medicine</article-title>
        <source>Nat. Rev. Genet.</source>
        <year>2016</year>
        <volume>17</volume>
        <fpage>507</fpage>
        <lpage>522</lpage>
        <pub-id pub-id-type="doi">10.1038/nrg.2016.86</pub-id>
        <?supplied-pmid 27528417?>
        <pub-id pub-id-type="pmid">27528417</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Harper</surname>
            <given-names>AR</given-names>
          </name>
          <name>
            <surname>Nayee</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Topol</surname>
            <given-names>EJ</given-names>
          </name>
        </person-group>
        <article-title>Protective alleles and modifier variants in human health and disease</article-title>
        <source>Nat. Rev. Genet.</source>
        <year>2015</year>
        <volume>16</volume>
        <fpage>689</fpage>
        <lpage>701</lpage>
        <pub-id pub-id-type="doi">10.1038/nrg4017</pub-id>
        <?supplied-pmid 26503796?>
        <pub-id pub-id-type="pmid">26503796</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>King</surname>
            <given-names>EA</given-names>
          </name>
          <name>
            <surname>Davis</surname>
            <given-names>JW</given-names>
          </name>
          <name>
            <surname>Degner</surname>
            <given-names>JF</given-names>
          </name>
        </person-group>
        <article-title>Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval</article-title>
        <source>PLoS Genet.</source>
        <year>2019</year>
        <volume>15</volume>
        <fpage>e1008489</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pgen.1008489</pub-id>
        <?supplied-pmid 31830040?>
        <pub-id pub-id-type="pmid">31830040</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Nelson</surname>
            <given-names>MR</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The support of human genetic evidence for approved drug indications</article-title>
        <source>Nat. Genet.</source>
        <year>2015</year>
        <volume>47</volume>
        <fpage>856</fpage>
        <lpage>860</lpage>
        <pub-id pub-id-type="doi">10.1038/ng.3314</pub-id>
        <?supplied-pmid 26121088?>
        <pub-id pub-id-type="pmid">26121088</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Claussnitzer</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A brief history of human disease genetics</article-title>
        <source>Nature</source>
        <year>2020</year>
        <volume>577</volume>
        <fpage>179</fpage>
        <lpage>189</lpage>
        <pub-id pub-id-type="doi">10.1038/s41586-019-1879-7</pub-id>
        <?supplied-pmid 31915397?>
        <pub-id pub-id-type="pmid">31915397</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Canela-Xandri</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Rawlik</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Tenesa</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>An atlas of genetic associations in UK Biobank</article-title>
        <source>Nat. Genet.</source>
        <year>2018</year>
        <volume>50</volume>
        <fpage>1593</fpage>
        <lpage>1599</lpage>
        <pub-id pub-id-type="doi">10.1038/s41588-018-0248-z</pub-id>
        <?supplied-pmid 6707814?>
        <pub-id pub-id-type="pmid">30349118</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cirulli</surname>
            <given-names>ET</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Genome-wide rare variant analysis for thousands of phenotypes in over 70,000 exomes from two cohorts</article-title>
        <source>Nat. Commun.</source>
        <year>2020</year>
        <volume>11</volume>
        <fpage>542</fpage>
        <pub-id pub-id-type="doi">10.1038/s41467-020-14288-y</pub-id>
        <?supplied-pmid 31992710?>
        <pub-id pub-id-type="pmid">31992710</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Van Hout</surname>
            <given-names>CV</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Exome sequencing and characterization of 49,960 individuals in the UK Biobank</article-title>
        <source>Nature</source>
        <year>2020</year>
        <volume>586</volume>
        <fpage>749</fpage>
        <lpage>756</lpage>
        <pub-id pub-id-type="doi">10.1038/s41586-020-2853-0</pub-id>
        <?supplied-pmid 33087929?>
        <pub-id pub-id-type="pmid">33087929</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>W</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Efficiently controlling for case–control imbalance and sample relatedness in large-scale genetic association studies</article-title>
        <source>Nat. Genet.</source>
        <year>2018</year>
        <volume>50</volume>
        <fpage>1335</fpage>
        <lpage>1341</lpage>
        <pub-id pub-id-type="doi">10.1038/s41588-018-0184-y</pub-id>
        <?supplied-pmid 6119127?>
        <pub-id pub-id-type="pmid">30104761</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sinnott-Armstrong</surname>
            <given-names>N</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Genetics of 35 blood and urine biomarkers in the UK Biobank</article-title>
        <source>Nat. Genet.</source>
        <year>2021</year>
        <volume>53</volume>
        <fpage>185</fpage>
        <lpage>194</lpage>
        <pub-id pub-id-type="doi">10.1038/s41588-020-00757-z</pub-id>
        <?supplied-pmid 33462484?>
        <pub-id pub-id-type="pmid">33462484</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kosmicki</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Churchhouse</surname>
            <given-names>CL</given-names>
          </name>
          <name>
            <surname>Rivas</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Neale</surname>
            <given-names>BM</given-names>
          </name>
        </person-group>
        <article-title>Discovery of rare variants for complex phenotypes</article-title>
        <source>Hum. Genet.</source>
        <year>2016</year>
        <volume>135</volume>
        <fpage>625</fpage>
        <lpage>634</lpage>
        <pub-id pub-id-type="doi">10.1007/s00439-016-1679-1</pub-id>
        <?supplied-pmid 27221085?>
        <pub-id pub-id-type="pmid">27221085</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Greene</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Richardson</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Turro</surname>
            <given-names>E</given-names>
          </name>
        </person-group>
        <article-title>A fast association test for identifying pathogenic variants involved in rare diseases</article-title>
        <source>Am. J. Hum. Genet.</source>
        <year>2017</year>
        <volume>101</volume>
        <fpage>104</fpage>
        <lpage>114</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ajhg.2017.05.015</pub-id>
        <?supplied-pmid 28669401?>
        <pub-id pub-id-type="pmid">28669401</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Povysil</surname>
            <given-names>G</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Rare-variant collapsing analyses for complex traits: guidelines and applications</article-title>
        <source>Nat. Rev. Genet.</source>
        <year>2019</year>
        <volume>20</volume>
        <fpage>747</fpage>
        <lpage>759</lpage>
        <pub-id pub-id-type="doi">10.1038/s41576-019-0177-4</pub-id>
        <?supplied-pmid 31605095?>
        <pub-id pub-id-type="pmid">31605095</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Petrovski</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>An exome sequencing study to assess the role of rare genetic variation in pulmonary fibrosis</article-title>
        <source>Am. J. Respir. Crit. Care Med.</source>
        <year>2017</year>
        <volume>196</volume>
        <fpage>82</fpage>
        <lpage>93</lpage>
        <pub-id pub-id-type="doi">10.1164/rccm.201610-2088OC</pub-id>
        <?supplied-pmid 28099038?>
        <pub-id pub-id-type="pmid">28099038</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cameron-Christie</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Exome-based rare-variant analyses in CKD</article-title>
        <source>J. Am. Soc. Nephrol.</source>
        <year>2019</year>
        <volume>30</volume>
        <fpage>1109</fpage>
        <lpage>1122</lpage>
        <pub-id pub-id-type="doi">10.1681/ASN.2018090909</pub-id>
        <?supplied-pmid 31085678?>
        <pub-id pub-id-type="pmid">31085678</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cirulli</surname>
            <given-names>ET</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways</article-title>
        <source>Science</source>
        <year>2015</year>
        <volume>347</volume>
        <fpage>1436</fpage>
        <lpage>1441</lpage>
        <pub-id pub-id-type="doi">10.1126/science.aaa3650</pub-id>
        <?supplied-pmid 25700176?>
        <pub-id pub-id-type="pmid">25700176</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>Epi4K Consortium &amp; Epilepsy Phenome/Genome Project.</collab>
        </person-group>
        <article-title>Ultra-rare genetic variation in common epilepsies: a case–control sequencing study</article-title>
        <source>Lancet Neurol.</source>
        <year>2017</year>
        <volume>16</volume>
        <fpage>135</fpage>
        <lpage>143</lpage>
        <pub-id pub-id-type="doi">10.1016/S1474-4422(16)30359-3</pub-id>
        <pub-id pub-id-type="pmid">28102150</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Carss</surname>
            <given-names>KJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Spontaneous coronary artery dissection: insights on rare genetic variation from genome sequencing</article-title>
        <source>Circ. Genom. Precis. Med.</source>
        <year>2020</year>
        <volume>13</volume>
        <fpage>e003030</fpage>
        <pub-id pub-id-type="doi">10.1161/CIRCGEN.120.003030</pub-id>
        <?supplied-pmid 33125268?>
        <pub-id pub-id-type="pmid">33125268</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Povysil</surname>
            <given-names>G</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Assessing the role of rare genetic variation in patients with heart failure</article-title>
        <source>JAMA Cardiol.</source>
        <year>2021</year>
        <volume>6</volume>
        <fpage>379</fpage>
        <lpage>386</lpage>
        <pub-id pub-id-type="doi">10.1001/jamacardio.2020.6500</pub-id>
        <?supplied-pmid 33326012?>
        <pub-id pub-id-type="pmid">33326012</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dhindsa</surname>
            <given-names>RS</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Identification of a missense variant in SPDL1 associated with idiopathic pulmonary fibrosis</article-title>
        <source>Commun. Biol.</source>
        <year>2021</year>
        <volume>4</volume>
        <fpage>392</fpage>
        <pub-id pub-id-type="doi">10.1038/s42003-021-01910-y</pub-id>
        <?supplied-pmid 33758299?>
        <pub-id pub-id-type="pmid">33758299</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Millard</surname>
            <given-names>LAC</given-names>
          </name>
          <name>
            <surname>Davies</surname>
            <given-names>NM</given-names>
          </name>
          <name>
            <surname>Gaunt</surname>
            <given-names>TR</given-names>
          </name>
          <name>
            <surname>Davey Smith</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Tilling</surname>
            <given-names>K</given-names>
          </name>
        </person-group>
        <article-title>Software application profile: PHESANT: a tool for performing automated phenome scans in UK Biobank</article-title>
        <source>Int. J. Epidemiol.</source>
        <year>2018</year>
        <volume>47</volume>
        <fpage>29</fpage>
        <lpage>35</lpage>
        <pub-id pub-id-type="doi">10.1093/ije/dyx204</pub-id>
        <?supplied-pmid 29040602?>
        <pub-id pub-id-type="pmid">29040602</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Petrovski</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Goldstein</surname>
            <given-names>DB</given-names>
          </name>
        </person-group>
        <article-title>Unequal representation of genetic variation across ancestry groups creates healthcare inequality in the application of precision medicine</article-title>
        <source>Genome Biol.</source>
        <year>2016</year>
        <volume>17</volume>
        <fpage>157</fpage>
        <pub-id pub-id-type="doi">10.1186/s13059-016-1016-y</pub-id>
        <?supplied-pmid 27418169?>
        <pub-id pub-id-type="pmid">27418169</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>DeBoever</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Medical relevance of protein-truncating variants across 337,205 individuals in the UK Biobank study</article-title>
        <source>Nat. Commun.</source>
        <year>2018</year>
        <volume>9</volume>
        <fpage>1612</fpage>
        <pub-id pub-id-type="doi">10.1038/s41467-018-03910-9</pub-id>
        <?supplied-pmid 29691392?>
        <pub-id pub-id-type="pmid">29691392</pub-id>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Karczewski</surname>
            <given-names>KJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The mutational constraint spectrum quantified from variation in 141,456 humans</article-title>
        <source>Nature</source>
        <year>2020</year>
        <volume>581</volume>
        <fpage>434</fpage>
        <lpage>443</lpage>
        <pub-id pub-id-type="doi">10.1038/s41586-020-2308-7</pub-id>
        <?supplied-pmid 7334197?>
        <pub-id pub-id-type="pmid">32461654</pub-id>
      </element-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Emdin</surname>
            <given-names>CA</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease</article-title>
        <source>Nat. Commun.</source>
        <year>2018</year>
        <volume>9</volume>
        <fpage>1613</fpage>
        <pub-id pub-id-type="doi">10.1038/s41467-018-03911-8</pub-id>
        <?supplied-pmid 29691411?>
        <pub-id pub-id-type="pmid">29691411</pub-id>
      </element-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>MacArthur</surname>
            <given-names>DG</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A systematic survey of loss-of-function variants in human protein-coding genes</article-title>
        <source>Science</source>
        <year>2012</year>
        <volume>335</volume>
        <fpage>823</fpage>
        <lpage>828</lpage>
        <pub-id pub-id-type="doi">10.1126/science.1215040</pub-id>
        <?supplied-pmid 22344438?>
        <pub-id pub-id-type="pmid">22344438</pub-id>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Landrum</surname>
            <given-names>MJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>ClinVar: improving access to variant interpretations and supporting evidence</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2018</year>
        <volume>46</volume>
        <fpage>D1062</fpage>
        <lpage>D1067</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkx1153</pub-id>
        <pub-id pub-id-type="pmid">29165669</pub-id>
      </element-citation>
    </ref>
    <ref id="CR31">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Buniello</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2019</year>
        <volume>47</volume>
        <fpage>D1005</fpage>
        <lpage>D1012</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gky1120</pub-id>
        <?supplied-pmid 30445434?>
        <pub-id pub-id-type="pmid">30445434</pub-id>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Amberger</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Bocchini</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Schiettecatte</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Scott</surname>
            <given-names>AF</given-names>
          </name>
          <name>
            <surname>Hamosh</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2015</year>
        <volume>43</volume>
        <fpage>D789</fpage>
        <lpage>D798</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gku1205</pub-id>
        <?supplied-pmid 25428349?>
        <pub-id pub-id-type="pmid">25428349</pub-id>
      </element-citation>
    </ref>
    <ref id="CR33">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>X</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The impact of rare variation on gene expression across tissues</article-title>
        <source>Nature</source>
        <year>2017</year>
        <volume>550</volume>
        <fpage>239</fpage>
        <lpage>243</lpage>
        <pub-id pub-id-type="doi">10.1038/nature24267</pub-id>
        <?supplied-pmid 29022581?>
        <pub-id pub-id-type="pmid">29022581</pub-id>
      </element-citation>
    </ref>
    <ref id="CR34">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mbatchou</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Computationally efficient whole-genome regression for quantitative and binary traits</article-title>
        <source>Nat. Genet.</source>
        <year>2021</year>
        <volume>53</volume>
        <fpage>1097</fpage>
        <lpage>1103</lpage>
        <pub-id pub-id-type="doi">10.1038/s41588-021-00870-7</pub-id>
        <?supplied-pmid 34017140?>
        <pub-id pub-id-type="pmid">34017140</pub-id>
      </element-citation>
    </ref>
    <ref id="CR35">
      <label>35.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Traynelis</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Optimizing genomic medicine in epilepsy through a gene-customized approach to missense variant interpretation</article-title>
        <source>Genome Res.</source>
        <year>2017</year>
        <volume>27</volume>
        <fpage>1715</fpage>
        <lpage>1729</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.226589.117</pub-id>
        <?supplied-pmid 28864458?>
        <pub-id pub-id-type="pmid">28864458</pub-id>
      </element-citation>
    </ref>
    <ref id="CR36">
      <label>36.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Weidinger</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Filaggrin mutations, atopic eczema, hay fever, and asthma in children</article-title>
        <source>J. Allergy Clin. Immunol.</source>
        <year>2008</year>
        <volume>121</volume>
        <fpage>1203</fpage>
        <lpage>1209.e1</lpage>
        <pub-id pub-id-type="doi">10.1016/j.jaci.2008.02.014</pub-id>
        <?supplied-pmid 18396323?>
        <pub-id pub-id-type="pmid">18396323</pub-id>
      </element-citation>
    </ref>
    <ref id="CR37">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kezic</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Loss-of-function mutations in filaggrin gene and malignant melanoma</article-title>
        <source>J. Eur. Acad. Dermatol. Venereol.</source>
        <year>2018</year>
        <volume>32</volume>
        <fpage>193</fpage>
        <pub-id pub-id-type="doi">10.1111/jdv.14813</pub-id>
        <?supplied-pmid 29465831?>
        <pub-id pub-id-type="pmid">29465831</pub-id>
      </element-citation>
    </ref>
    <ref id="CR38">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kaae</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Filaggrin gene mutations and risk of basal cell carcinoma</article-title>
        <source>Br. J. Dermatol.</source>
        <year>2013</year>
        <volume>169</volume>
        <fpage>1162</fpage>
        <lpage>1164</lpage>
        <pub-id pub-id-type="doi">10.1111/bjd.12573</pub-id>
        <?supplied-pmid 23927042?>
        <pub-id pub-id-type="pmid">23927042</pub-id>
      </element-citation>
    </ref>
    <ref id="CR39">
      <label>39.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Thyssen</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Elias</surname>
            <given-names>PM</given-names>
          </name>
        </person-group>
        <article-title>It remains unknown whether filaggrin gene mutations evolved to increase cutaneous synthesis of vitamin D</article-title>
        <source>Genome Biol. Evol.</source>
        <year>2017</year>
        <volume>9</volume>
        <fpage>900</fpage>
        <lpage>901</lpage>
        <pub-id pub-id-type="doi">10.1093/gbe/evx049</pub-id>
        <?supplied-pmid 28338939?>
        <pub-id pub-id-type="pmid">28338939</pub-id>
      </element-citation>
    </ref>
    <ref id="CR40">
      <label>40.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pagnamenta</surname>
            <given-names>AT</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Exome sequencing can detect pathogenic mosaic mutations present at low allele frequencies</article-title>
        <source>J. Hum. Genet.</source>
        <year>2012</year>
        <volume>57</volume>
        <fpage>70</fpage>
        <lpage>72</lpage>
        <pub-id pub-id-type="doi">10.1038/jhg.2011.128</pub-id>
        <?supplied-pmid 22129557?>
        <pub-id pub-id-type="pmid">22129557</pub-id>
      </element-citation>
    </ref>
    <ref id="CR41">
      <label>41.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ben-Eghan</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Don’t ignore genetic data from minority populations</article-title>
        <source>Nature</source>
        <year>2020</year>
        <volume>585</volume>
        <fpage>184</fpage>
        <lpage>186</lpage>
        <pub-id pub-id-type="doi">10.1038/d41586-020-02547-3</pub-id>
        <?supplied-pmid 32901124?>
        <pub-id pub-id-type="pmid">32901124</pub-id>
      </element-citation>
    </ref>
    <ref id="CR42">
      <label>42.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Diogo</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Phenome-wide association studies across large population cohorts support drug target validation</article-title>
        <source>Nat. Commun.</source>
        <year>2018</year>
        <volume>9</volume>
        <fpage>4285</fpage>
        <pub-id pub-id-type="doi">10.1038/s41467-018-06540-3</pub-id>
        <?supplied-pmid 30327483?>
        <pub-id pub-id-type="pmid">30327483</pub-id>
      </element-citation>
    </ref>
    <ref id="CR43">
      <label>43.</label>
      <mixed-citation publication-type="other">Cameron-Christie, S. et al. A broad exome study of the genetic architecture of asthma reveals novel patient subgroups. Preprint at 10.1101/2020.12.10.419663 (2020).</mixed-citation>
    </ref>
    <ref id="CR44">
      <label>44.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Loh</surname>
            <given-names>PR</given-names>
          </name>
          <name>
            <surname>Kichaev</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Gazal</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Schoech</surname>
            <given-names>AP</given-names>
          </name>
          <name>
            <surname>Price</surname>
            <given-names>AL</given-names>
          </name>
        </person-group>
        <article-title>Mixed-model association for biobank-scale datasets</article-title>
        <source>Nat. Genet.</source>
        <year>2018</year>
        <volume>50</volume>
        <fpage>906</fpage>
        <lpage>908</lpage>
        <pub-id pub-id-type="doi">10.1038/s41588-018-0144-6</pub-id>
        <?supplied-pmid 29892013?>
        <pub-id pub-id-type="pmid">29892013</pub-id>
      </element-citation>
    </ref>
    <ref id="CR45">
      <label>45.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Loh</surname>
            <given-names>PR</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Efficient Bayesian mixed-model analysis increases association power in large cohorts</article-title>
        <source>Nat. Genet.</source>
        <year>2015</year>
        <volume>47</volume>
        <fpage>284</fpage>
        <lpage>290</lpage>
        <pub-id pub-id-type="doi">10.1038/ng.3190</pub-id>
        <?supplied-pmid 4342297?>
        <pub-id pub-id-type="pmid">25642633</pub-id>
      </element-citation>
    </ref>
    <ref id="CR46">
      <label>46.</label>
      <mixed-citation publication-type="other">Informa. Pharmaprojects: track pharma R&amp;D. <italic>Informa</italic><ext-link ext-link-type="uri" xlink:href="https://pharmaintelligence.informa.com/products-and-services/data-and-analysis/pharmaprojects">https://pharmaintelligence.informa.com/products-and-services/data-and-analysis/pharmaprojects</ext-link> (2021).</mixed-citation>
    </ref>
    <ref id="CR47">
      <label>47.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sudlow</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age</article-title>
        <source>PLoS Med.</source>
        <year>2015</year>
        <volume>12</volume>
        <fpage>e1001779</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pmed.1001779</pub-id>
        <?supplied-pmid 4380465?>
        <pub-id pub-id-type="pmid">25826379</pub-id>
      </element-citation>
    </ref>
    <ref id="CR48">
      <label>48.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cingolani</surname>
            <given-names>P</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of <italic>Drosophila melanogaster</italic> strain w1118; iso-2; iso-3</article-title>
        <source>Fly (Austin)</source>
        <year>2012</year>
        <volume>6</volume>
        <fpage>80</fpage>
        <lpage>92</lpage>
        <pub-id pub-id-type="doi">10.4161/fly.19695</pub-id>
        <pub-id pub-id-type="pmid">22728672</pub-id>
      </element-citation>
    </ref>
    <ref id="CR49">
      <label>49.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Howe</surname>
            <given-names>KL</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Ensembl 2021</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2021</year>
        <volume>49</volume>
        <fpage>D884</fpage>
        <lpage>D891</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkaa942</pub-id>
        <?supplied-pmid 33137190?>
        <pub-id pub-id-type="pmid">33137190</pub-id>
      </element-citation>
    </ref>
    <ref id="CR50">
      <label>50.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ioannidis</surname>
            <given-names>NM</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>REVEL: an Ensemble method for predicting the pathogenicity of rare missense variants</article-title>
        <source>Am. J. Hum. Genet.</source>
        <year>2016</year>
        <volume>99</volume>
        <fpage>877</fpage>
        <lpage>885</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ajhg.2016.08.016</pub-id>
        <?supplied-pmid 27666373?>
        <pub-id pub-id-type="pmid">27666373</pub-id>
      </element-citation>
    </ref>
    <ref id="CR51">
      <label>51.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jun</surname>
            <given-names>G</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Detecting and estimating contamination of human DNA samples in sequencing and array-based genotype data</article-title>
        <source>Am. J. Hum. Genet.</source>
        <year>2012</year>
        <volume>91</volume>
        <fpage>839</fpage>
        <lpage>848</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ajhg.2012.09.004</pub-id>
        <?supplied-pmid 23103226?>
        <pub-id pub-id-type="pmid">23103226</pub-id>
      </element-citation>
    </ref>
    <ref id="CR52">
      <label>52.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pujar</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Consensus coding sequence (CCDS) database: a standardized set of human and mouse protein-coding regions supported by expert curation</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2018</year>
        <volume>46</volume>
        <fpage>D221</fpage>
        <lpage>D228</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkx1031</pub-id>
        <?supplied-pmid 29126148?>
        <pub-id pub-id-type="pmid">29126148</pub-id>
      </element-citation>
    </ref>
    <ref id="CR53">
      <label>53.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Manichaikul</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Robust relationship inference in genome-wide association studies</article-title>
        <source>Bioinformatics</source>
        <year>2010</year>
        <volume>26</volume>
        <fpage>2867</fpage>
        <lpage>2873</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btq559</pub-id>
        <?supplied-pmid 20926424?>
        <pub-id pub-id-type="pmid">20926424</pub-id>
      </element-citation>
    </ref>
    <ref id="CR54">
      <label>54.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hanscombe</surname>
            <given-names>KB</given-names>
          </name>
          <name>
            <surname>Coleman</surname>
            <given-names>JRI</given-names>
          </name>
          <name>
            <surname>Traylor</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lewis</surname>
            <given-names>CM</given-names>
          </name>
        </person-group>
        <article-title>ukbtools: An R package to manage and query UK Biobank data</article-title>
        <source>PLoS ONE</source>
        <year>2019</year>
        <volume>14</volume>
        <fpage>e0214311</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0214311</pub-id>
        <?supplied-pmid 31150407?>
        <pub-id pub-id-type="pmid">31150407</pub-id>
      </element-citation>
    </ref>
    <ref id="CR55">
      <label>55.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pedersen</surname>
            <given-names>BS</given-names>
          </name>
          <name>
            <surname>Quinlan</surname>
            <given-names>AR</given-names>
          </name>
        </person-group>
        <article-title>Who’s who? Detecting and resolving sample anomalies in human DNA sequencing studies with Peddy</article-title>
        <source>Am. J. Hum. Genet.</source>
        <year>2017</year>
        <volume>100</volume>
        <fpage>406</fpage>
        <lpage>413</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ajhg.2017.01.017</pub-id>
        <?supplied-pmid 28190455?>
        <pub-id pub-id-type="pmid">28190455</pub-id>
      </element-citation>
    </ref>
    <ref id="CR56">
      <label>56.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tin</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels</article-title>
        <source>Nat. Genet.</source>
        <year>2019</year>
        <volume>51</volume>
        <fpage>1459</fpage>
        <lpage>1474</lpage>
        <pub-id pub-id-type="doi">10.1038/s41588-019-0504-x</pub-id>
        <?supplied-pmid 31578528?>
        <pub-id pub-id-type="pmid">31578528</pub-id>
      </element-citation>
    </ref>
    <ref id="CR57">
      <label>57.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Olafsson</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Common and rare sequence variants influencing tumor biomarkers in blood</article-title>
        <source>Cancer Epidemiol. Biomarkers Prev.</source>
        <year>2020</year>
        <volume>29</volume>
        <fpage>225</fpage>
        <lpage>235</lpage>
        <?supplied-pmid 31666285?>
        <pub-id pub-id-type="pmid">31666285</pub-id>
      </element-citation>
    </ref>
    <ref id="CR58">
      <label>58.</label>
      <mixed-citation publication-type="other">Annis, A. et al. Determining genome-wide significance thresholds in biobanks with thousands of phenotypes: a case study using the Michigan Genomics Initiative. Presented at Annual Meeting of The American Society of Human Genetics 2019 (2019).</mixed-citation>
    </ref>
    <ref id="CR59">
      <label>59.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wishart</surname>
            <given-names>DS</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2018</year>
        <volume>46</volume>
        <fpage>D1074</fpage>
        <lpage>D1082</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkx1037</pub-id>
        <?supplied-pmid 29126136?>
        <pub-id pub-id-type="pmid">29126136</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
